<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./536.胚胎干细胞 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app201.us.archive.org';v.server_ms=408;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./536.胚胎干细胞 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./536.胚胎干细胞 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d10536.htm","20221028211915","https://web.archive.org/","web","/_static/",
	      "1666991955");
</script>
<link rel="stylesheet" type="text/css" href="./536.胚胎干细胞 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./536.胚胎干细胞 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="胚胎干细胞 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221028211915im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./536.胚胎干细胞 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./536.胚胎干细胞 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./536.胚胎干细胞 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./536.胚胎干细胞 - 搜狗科学百科_files/highlight.min.css"><title>胚胎干细胞 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style>
<!--百度统计-->
<script>
   var _hmt = _hmt || [];
   (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
      var s = document.getElementsByTagName("script")[0]; 
      s.parentNode.insertBefore(hm, s);
      })();
</script>

	<!--百度统计-->
	<script>
		var _hmt = _hmt || [];
		(function() {
			var hm = document.createElement("script");
			hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
			var s = document.getElementsByTagName("script")[0]; 
			s.parentNode.insertBefore(hm, s);
			})();
	</script>
</head>
<body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d10536.htm","20221028211915",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('98ed50c0fabb4cc5b3773ba479450179') window._gtag.traceId = '98ed50c0fabb4cc5b3773ba479450179';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221028211915/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221028211915/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221028211915/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221028211915/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221028211915/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221028211915/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221028211915/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221028211915/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221028211915/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>胚胎干细胞</h1><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="54114251534557443"><div class="text_img ed_imgfloat_right"><a class="ed_image_link" data-src="https://img01.sogoucdn.com/app/a/200698/sogou_science_12985" data-bigsrc="https://img01.sogoucdn.com/app/a/200698/sogou_science_12985?width=231&amp;height=174&amp;titlename=%E7%BB%86%E8%83%9E%E5%9F%B9%E5%85%BB%E4%B8%AD%E7%9A%84%E4%BA%BA%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E&amp;w=300&amp;h=225" title="点击查看大图" data-w="300" data-h="225" style="background-image:url(https://web.archive.org/web/20221028211915im_/https://img01.sogoucdn.com/app/a/200698/sogou_science_12985)" href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#!"></a><div class="text_img_title" style="text-align: center;">细胞培养中的人胚胎干细胞</div></div><div><p><b>胚胎干细胞（Embryonic stem cells,ES细胞或ESCs）</b>是来源于囊胚内细胞团的多能干细胞，而囊胚是胚胎植入前早期的一个阶段。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_2" class="kx_ref">[2]</a></sup> 人类胚胎在受精后4-5天到达囊胚期，此时的胚胎由50-150个细胞组成。分离胚结或内细胞团（ICM）会导致囊胚的破坏，这一过程会引发伦理问题，包括植入前阶段的胚胎是否应具有与植入后发育阶段的胚胎相同的道德考虑。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_3" class="kx_ref">[3]</a></sup><sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_4" class="kx_ref">[4]</a></sup> 研究人员目前非常关注胚胎干细胞的治疗潜力，因为临床应用是许多实验室的目标。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_5" class="kx_ref">[5]</a></sup>潜在用途包括治疗糖尿病和心脏病。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_5" class="kx_ref">[5]</a></sup> 这些细胞正被研究用于临床治疗、遗传疾病模型和细胞/脱氧核糖核酸（DNA）修复。然而，研究和临床过程中的副作用，如肿瘤和免疫排斥反应也有报道。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_6" class="kx_ref">[6]</a></sup> </p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col3"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14995394979168780">特性</a></li><li class="secondary_catalog"><span>1.1 </span><a href="javascript:" data-id="14995394979168780">多能性</a></li><li class="secondary_catalog"><span>1.2 </span><a href="javascript:" data-id="14995394979168780">自我更新</a></li><li class="secondary_catalog"><span>1.3 </span><a href="javascript:" data-id="14995394979168780">增殖</a></li><li class="secondary_catalog"><span>1.4 </span><a href="javascript:" data-id="14995394979168780">用途</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14995394979168781">应用</a></li><li class="secondary_catalog"><span>2.1 </span><a href="javascript:" data-id="14995394979168781">细胞替代疗法</a></li><li class="secondary_catalog"><span>2.2 </span><a href="javascript:" data-id="14995394979168781">临床潜力</a></li><li class="secondary_catalog"><span>2.3 </span><a href="javascript:" data-id="14995394979168781">药物发现</a></li></ul><ul class="catalog_list col3"><li class="secondary_catalog"><span>2.4 </span><a href="javascript:" data-id="14995394979168781">遗传疾病模型</a></li><li class="secondary_catalog"><span>2.5 </span><a href="javascript:" data-id="14995394979168781">DNA损伤修复<b>（脱氧核糖核酸损伤修复）</b></a></li><li class="secondary_catalog"><span>2.6 </span><a href="javascript:" data-id="14995394979168781">临床试验</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14995394979168782">关注和争议</a></li><li class="secondary_catalog"><span>3.1 </span><a href="javascript:" data-id="14995394979168782"><b>负面效应</b></a></li><li class="secondary_catalog"><span>3.2 </span><a href="javascript:" data-id="14995394979168782">伦理争论</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14995394979168783">历史</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14995394995945987">胚胎干细胞的来源和培养的技术和条件</a></li></ul><ul class="catalog_list col3"><li class="secondary_catalog"><span>5.1 </span><a href="javascript:" data-id="14995394995945987">源自人类</a></li><li class="secondary_catalog"><span>5.2 </span><a href="javascript:" data-id="14995394995945987"><b>源</b>自其他动物</a></li><li class="secondary_catalog"><span>5.3 </span><a href="javascript:" data-id="14995394995945987">新<b>细胞系来源的潜在方法</b></a></li><li class="secondary_catalog"><span>5.4 </span><a href="javascript:" data-id="14995394995945987">诱导多能干细胞</a></li><li class="secondary_catalog"><span>5.5 </span><a href="javascript:" data-id="14995394995945987"><b>细胞培养中的试剂污染</b></a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14995394979168780"><h2 class="title">1 特性<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img04.sogoucdn.com/app/a/200698/sogou_science_12987" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;">胚胎干细胞的转录组</div>   
        </div> <p></p><p>胚胎干细胞(ESCs)来源于早期哺乳动物胚胎的囊胚阶段，其特点是能够分化成任何类型胚胎细胞，并具有自我更新的能力。正是这些特性使它们在科学和医学领域具有价值。胚胎干细胞具有正常的核型，保持高端粒酶活性，并表现出显著的长期增殖潜力。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_7" class="kx_ref">[7]</a></sup> </p><p></p><h3>1.1 <span>多能性</span></h3><p></p><p>内细胞团的胚胎干细胞具有多能性，这意味着它们能够分化产生原始外胚层，在原肠胚形成过程中最终分化为三个初级胚层的所有衍生物：外胚层、内胚层和中胚层。这些胚层在成人体内生成220多种类型细胞中的每一种。当提供适当的信号时，胚胎干细胞最初形成前体细胞，随后分化成所需的细胞类型。多能性将胚胎干细胞与成体干细胞区分开来，成体干细胞是专能性的，只能产生有限数量的细胞类型。</p><p></p><h3>1.2 <span>自我更新</span></h3><p></p><p>在特定条件下，胚胎干细胞能够在未分化状态下无限期自我更新。自我更新的条件是必须防止细胞聚集并维持一个使其处于不分化状态的环境。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_8" class="kx_ref">[8]</a></sup> 通常这是在实验室用含有血清和白血病抑制因子的培养基或含有两种抑制药物(甲乙酮抑制剂PD03259010和GSK-3抑制剂CHIR99021，“2i”)的无血清培养基来实现的。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_9" class="kx_ref">[9]</a></sup> </p><p></p><h3>1.3 <span>增殖</span></h3><p></p><p>由于细胞周期中G1期缩短，胚胎干细胞分裂非常频繁。快速的细胞分裂使细胞数量快速增加，而不是细胞大小增加，这对早期胚胎发育很重要。在胚胎干细胞中，参与细胞周期G1/S转换的细胞周期蛋白A和细胞周期蛋白E总是高水平表达。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_10" class="kx_ref">[10]</a></sup> 促进细胞周期进程的细胞周期蛋白依赖性激酶，如CDK2，部分原因是由于其抑制因子的下调而过度激活。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_11" class="kx_ref">[11]</a></sup> 视网膜母细胞瘤蛋白抑制转录因子E2F，直到细胞准备进入S期，但在胚胎干细胞中视网膜母细胞瘤蛋白被过度磷酸化而失活，导致增殖基因的持续表达。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_10" class="kx_ref">[10]</a></sup> 这些变化导致细胞分裂周期加快。尽管缩短的G1期与胚胎干细胞的多能性[12]维持有关，但在含两种抑制药物的无血清条件下生长的胚胎干细胞确实表达低磷酸化活性的视网膜母细胞瘤蛋白，并具有延长的G1期<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_12" class="kx_ref">[12]</a></sup> <sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_13" class="kx_ref">[13]</a></sup>。尽管与含血清培养基中生长的胚胎干细胞相比，细胞周期有所不同，但这些细胞具有相似的多能性，多能因子Oct4和Nanog在转录调节胚胎干细胞细胞周期中发挥作用。</p><p></p><h3>1.4 <span>用途</span></h3><p></p><p>由于胚胎干细胞的可塑性和潜在的无限自我更新能力，胚胎干细胞疗法已被提议用于损伤或疾病后的再生医学和组织置换。多能干细胞在治疗多种不同疾病方面显示出前景，包括但不限于：脊髓损伤、年龄相关性黄斑变性、糖尿病、神经退行性疾病(如帕金森病)、艾滋病等。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_14" class="kx_ref">[14]</a></sup> 除了在再生医学方面的潜力外，胚胎干细胞还提供了组织或器官的一种可能的替代来源，这是解决供体短缺困境的一种办法。但是围绕这一点有一些伦理争议(见下面的伦理辩论部分)。除了这些用途之外，胚胎干细胞还可以用于人类早期发育、某些遗传疾病和体外毒理学试验的研究。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_7" class="kx_ref">[7]</a></sup> </p></div></div><div id="par_14995394979168781"><h2 class="title">2 应用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>根据2002年在《美国科学院院刊》（PNAS）上发表的一篇文章，“人类胚胎干细胞具有分化成各种细胞类型的潜力”，因此，可以用作移植或组织工程的细胞来源。”<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_15" class="kx_ref">[15]</a></sup> </p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img01.sogoucdn.com/app/a/200698/sogou_science_12988" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;">胚状体形成后24小时</div>   
        </div> <p></p><p>然而，胚胎干细胞的应用不局限于细胞/组织工程。</p><p></p><h3>2.1 <span>细胞替代疗法</span></h3><p></p><p>目前的研究集中在将胚胎干细胞分化成多种细胞类型，最终用作细胞替代疗法（CRTs）。一些已经或正在开发的细胞类型包括心肌细胞（CM）、神经元、肝细胞、骨髓细胞、胰岛细胞和内皮细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_16" class="kx_ref">[16]</a></sup> 然而，从胚胎干细胞中获得这种细胞类型并非没有障碍，因此目前的研究侧重于克服这些障碍。例如，研究人员正在研究将胚胎干细胞分化成组织特异性心肌细胞，以及根除它们与成人心肌细胞不同的不成熟的特性。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_17" class="kx_ref">[17]</a></sup> </p><p></p><h3>2.2 <span>临床潜力</span></h3><p></p><p>
 </p><ul>
  <li>研究人员已经将胚胎干细胞分化为产生多巴胺的细胞，希望这些神经元能够用于治疗帕金森氏病。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_18" class="kx_ref">[18]</a></sup><sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_19" class="kx_ref">[19]</a></sup></li>
  <li>胚胎干细胞已经分化为自然杀伤细胞（NK）和骨组织。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_20" class="kx_ref">[20]</a></sup></li>
  <li>胚胎干细胞用于治疗糖尿病的替代治疗正在研究中。例如，达穆尔等人能够将胚胎干细胞分化为产生胰岛素的细胞，<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_21" class="kx_ref">[21]</a></sup> 哈佛大学的研究人员能够从胚胎干细胞中产生大量胰岛β细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_22" class="kx_ref">[22]</a></sup></li>
  <li>发表在《欧洲心脏杂志》上的一篇文章描述了人类胚胎干细胞衍生心脏祖细胞的转化过程，并用于严重心力衰竭患者的临床试验。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_23" class="kx_ref">[23]</a></sup></li>
 </ul><p></p><p></p><h3>2.3 <span>药物发现</span></h3><p></p><p>除了成为器官移植的重要替代物外，胚胎干细胞还被用于毒理学领域和细胞筛选，以发现可以开发为小分子药物的新化学实体（NCEs）。研究表明，胚胎干细胞衍生的心肌细胞在体外模型中得到验证，可以用于测试药物反应和预测毒性特征。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_16" class="kx_ref">[16]</a></sup> 胚胎干细胞衍生的心肌细胞已被证明对药物刺激有反应，因此可用于评估心脏毒性，如尖端扭转型室性心动过速。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_24" class="kx_ref">[24]</a></sup> </p><p>胚胎干细胞衍生的肝细胞也是有用的模型，可用于药物发现的临床前阶段。然而，将胚胎干细胞分化为肝细胞已被证明是具有挑战性的，这阻碍了测试药物代谢的能力。因此，目前的研究集中在建立具有稳定的第一和第二阶段酶活性的全功能性胚胎干细胞衍生肝细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_25" class="kx_ref">[25]</a></sup> </p><p></p><h3>2.4 <span>遗传疾病模型</span></h3><p></p><p>几项新的研究已经开始探讨用胚胎干细胞模拟遗传疾病的概念。无论是通过基因操纵细胞，还是最近通过获得产前基因诊断（PGD）所鉴定的患病细胞系，利用干细胞模拟遗传疾病在某些方面已经获得成功。这种方法在研究诸如脆性X染色体综合征、囊性纤维化和其他没有可靠模型系统的遗传疾病方面可能非常有价值。</p><p>专攻胚胎和细胞遗传学(遗传细胞学)的俄裔美国医学研究者尤里·韦林斯基(YuryVerlinsky)开发了产前诊断的检测方法，比标准羊膜穿刺术早一个半月确定遗传和染色体异常。这种技术现在被许多孕妇和准父母所使用，特别是有遗传异常史的夫妇，或者超过35岁的妇女(患遗传相关疾病的风险更高)。此外，通过允许父母选择无遗传疾病的胚胎，他们有可能利用无疾病后代的细胞挽救已经患有类似疾病的兄弟姐妹的生命。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_26" class="kx_ref">[26]</a></sup> </p><p></p><h3>2.5 <span>DNA损伤修复（脱氧核糖核酸损伤修复）</span></h3><p></p><p>分化的体细胞和胚胎干细胞使用不同的策略来处理脱氧核糖核酸损伤。例如，人包皮成纤维细胞（一种体细胞）使用非同源末端连接(NHEJ)，这是一种容易出错的DNA修复过程，作为在所有细胞周期阶段修复双链断裂（DSBs）的主要途径。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_27" class="kx_ref">[27]</a></sup> 由于其易出错的性质，非同源末端连接修复途径倾向于在细胞克隆后代中产生突变。</p><p>胚胎干细胞使用不同的策略来应对双链断裂。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_28" class="kx_ref">[28]</a></sup> 因为胚胎干细胞产生一个生物体包括生殖系细胞在内的所有细胞类型，所以在胚胎干细胞中因错误的DNA修复而产生的突变比在已分化的体细胞中产生的突变更为严重。因此，胚胎干细胞需要强有力的机制来准确修复受损的基因，如果修复失败，则移除那些未修复的细胞。因此，小鼠胚胎干细胞主要通过高保真同源重组修复(HRR)来修复DSBs。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_28" class="kx_ref">[28]</a></sup> 这种类型的修复依赖于两条姐妹染色体的相互作用，这两条染色体在细胞周期的S期形成，在G2期同时存在。HRR可以通过利用来自另一条姐妹染色体的完整信息来精确修复其姐妹染色体中的DSB。处于细胞周期G1期的细胞(即中期/细胞分裂后但在下一轮复制前)每条染色体只有一个拷贝(即姐妹染色体不存在)。小鼠胚胎干细胞缺乏G1期检验点，在发生DNA损伤后不会经历细胞周期停滞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_29" class="kx_ref">[29]</a></sup> 更确切地说，它们启动细胞程序性死亡(凋亡)以应对DNA损伤。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_30" class="kx_ref">[30]</a></sup> 细胞凋亡可以作为一种故障安全策略，用于清除具有DNA损伤而未修复的细胞，以避免突变和癌症的发生。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_31" class="kx_ref">[31]</a></sup> 与这一策略相一致的是，小鼠胚胎干细胞的突变频率比同基因型的小鼠体细胞低约100倍。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_32" class="kx_ref">[32]</a></sup> </p><p></p><h3>2.6 <span>临床试验</span></h3><p></p><p>22009年1月23日，由人类胚胎干细胞衍生来的少突胶质细胞(大脑和脊髓的一种细胞类型)移植到脊髓损伤个体的第一阶段临床试验获得了美国食品和药物管理局(FDA)的批准，标志着世界上第一次人类胚胎干细胞的人类试验。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_33" class="kx_ref">[33]</a></sup> 这项推动该领域科学进步的研究是由加州大学欧文分校的汉斯·凯尔斯特德及其同事完成的，并得到了由迈克尔·韦斯特博士创建的加利福尼亚州门罗公园Geron公司的支持。先前的一项实验表明，将人类胚胎干细胞定向诱导成少突胶质细胞后移植到脊髓受损7天的大鼠体内，之后其运动恢复状况有所改善。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_34" class="kx_ref">[34]</a></sup> 第一阶段临床研究旨在招募大约8到10名截瘫患者，他们在试验开始前两周内受伤，因为必须在疤痕组织形成前注射细胞。研究人员强调，注射并不能完全治愈病人和恢复所有的活动能力。根据啮齿动物试验的结果，研究人员推测髓鞘的恢复和活动能力的增加可能会发生。第一次试验主要是为了测试该过程的安全性，如果一切顺利，希望它能促进人类更严重的伤残疾病的进一步研究。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_35" class="kx_ref">[35]</a></sup> 该试验于2009年8月暂停，原因是美国食品和药物管理局担心在几个经过治疗的大鼠模型中发现少量微小囊肿，但该暂停于2010年7月30日被解除。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_36" class="kx_ref">[36]</a></sup> </p><p>2010年10月，研究人员在亚特兰大的谢博德中心为第一个病人登记并实施了胚胎干细胞治疗。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_37" class="kx_ref">[37]</a></sup> 干细胞疗法的实施者Geron公司估计，干细胞的复制和GRNOPC1疗法成败的评估需要几个月的时间。</p><p>2011年11月，Geron公司宣布停止试验，并出于经济原因退出干细胞研究，但将继续监测现有患者，同时试图找到一个可以继续他们研究的合作伙伴。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_38" class="kx_ref">[38]</a></sup> 2013年，首席执行官迈克尔·韦斯特(Michael D. West)博士领导的BioTime公司收购了Geron公司的所有干细胞资产，宣称打算重启Gerron公司基于胚胎干细胞的脊髓损伤研究临床试验。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_39" class="kx_ref">[39]</a></sup> </p><p>BioTime公司旗下的阿斯特里亚生物治疗公司(纽约证券交易所MKT: AST)获得了加州再生医学研究所(CIRM)授予的1430万美元战略合作伙伴奖，以重新启动世界上第一个基于胚胎干细胞的人类脊髓损伤临床试验。在加州公共基金的支持下，CIRM是世界上干细胞相关研究和开发的最大资助者。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_40" class="kx_ref">[40]</a></sup> </p><p>该奖项为阿斯特里亚提供资金，用于在脊髓损伤受试者中重新启动AST-OPC1的临床开发，并扩大针对未来关键试验的目标人群中剂量递增的临床试验。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_40" class="kx_ref">[40]</a></sup> </p><p>AST-OPC1是人类胚胎干细胞（hESCs）衍生而来且含有少突胶质母细胞（OPCs）的细胞群。OPCs及其成熟衍生物-少突胶质细胞为脊髓和大脑中的神经细胞提供重要的功能支持。阿斯特里亚最近公布了在神经完全性胸脊髓损伤患者中低剂量AST-OPC1的第一阶段临床试验结果。结果表明，AST-OPC1被成功地递送到损伤的脊髓部位。在AST-OPC1给药后的2-3年内，患者在详细的随访评估(包括频繁的神经系统检查和核磁共振成像)中没有显示与细胞相关的严重不良事件的证据。移植后一年对受试者的免疫监测显示没有对AST-OPC1产生抗体或细胞免疫反应。五名受试者中的四名受试者，在2-3年随访期内进行的连续核磁共振成像扫描表明，脊髓空洞可能已经减少，AST-OPC1可能在减少脊髓组织恶化方面具有一定积极作用。根据脊髓损伤神经分类国际标准(ISNCSCI)检查的评估，试验中的五名受试者没有出现意外的神经退化或改善。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_40" class="kx_ref">[40]</a></sup> </p><p>来自CIRM的战略伙伴关系三期捐款将为阿斯特里亚斯提供资金，以支持AST-OPC1在脊髓损伤受试者中的下一次临床试验，并为阿斯特里亚斯的产品开发努力提供资金，以改进和扩大生产方法，支持后期试验并最终商业化。CIRM的资助将取决于美国食品和药物管理局对试验的批准、阿斯特里亚斯和CIRM之间最终协议的完成，以及阿斯特里亚斯在实现某些预定项目里程碑方面的持续进展。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_40" class="kx_ref">[40]</a></sup> </p></div></div><div id="par_14995394979168782"><h2 class="title">3 关注和争议<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>3.1 <span>负面效应</span></h3><p></p><p>将胚胎干细胞移植到患者体内作为治疗的主要关注点是它们具有形成肿瘤(包括畸胎瘤)的能力。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_41" class="kx_ref">[41]</a></sup> 安全问题促使美国食品和药物管理局暂停第一次胚胎干细胞临床试验，但是并没有观察到肿瘤的发生。</p><p>提高胚胎干细胞临床应用安全性的主要策略是将胚胎干细胞分化为特定的细胞类型(如神经元、肌肉、肝细胞)，这些细胞类型降低或消除了引起肿瘤的能力。分化后，通过流式细胞术对细胞进行分选以进一步纯化。胚胎干细胞从本质上推测比用基因整合病毒载体产生的诱导多能干细胞更安全，因为它们没有用与癌症相关的基因如c-Myc基因进行基因修饰。然而，诱导多能干细胞所需的基因在胚胎干细胞中表达量非常高，这些基因（包括Myc）对胚胎干细胞的自我更新和多能性至关重要，<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_42" class="kx_ref">[42]</a></sup> 并且通过消除c-Myc的表达量来提高安全性的潜在策略不太可能保持细胞的“干细胞性”。然而，N-myc和L-myc已经被发现可以在同等效率下替代c-myc来诱导多能干细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_43" class="kx_ref">[43]</a></sup>最近诱导多能性的方案通过使用非整合的核糖核酸病毒载体，如仙台病毒或信使核糖核酸（mRNA)转染，完全克服了这些问题。</p><p></p><h3>3.2 <span>伦理争论</span></h3><p></p><p>由于胚胎干细胞研究的性质，在这个问题上存在许多有争议的观点。由于获得胚胎干细胞需要摧毁从中获得这些细胞的胚胎，胚胎的伦理道德地位受到质疑。有些人认为，5天大的细胞团太年轻而不能称之为人，或者从体外受精诊所(实验室通常从那里获取胚胎)捐赠的胚胎，如果不加以利用最终都会变成医疗废弃物。胚胎干细胞研究的反对者则反驳说，任何胚胎都有可能成为人，因此摧毁它就是谋杀，胚胎必须受到与发育完全的人类与之相等的伦理观的保护。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_44" class="kx_ref">[44]</a></sup> </p></div></div><div id="par_14995394979168783"><h2 class="title">4 历史<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>
 </p><ul>
  <li>1964年:刘易斯·克莱因史密斯和小巴里·皮尔斯从畸胎瘤中分离出单一类型的细胞，畸胎瘤是一种现在已知的来源于生殖细胞的肿瘤。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_45" class="kx_ref">[45]</a></sup> 这些从畸胎瘤中分离出来的细胞作为干细胞在细胞培养中复制和生长，现在被称为胚胎癌细胞（EC）。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_46" class="kx_ref">[46]</a></sup> 虽然形态学和分化潜能(多能性)的相似性导致了使用胚胎癌细胞作为小鼠早期发育的体外模型，但<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_47" class="kx_ref">[47]</a></sup> 胚胎癌干细胞含有遗传突变和通常在畸胎瘤发展过程中积累的异常核型。这些遗传变异进一步增强了直接从内细胞团培养多能干细胞的需求。</li>
 </ul><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img04.sogoucdn.com/app/a/200698/sogou_science_12989" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">马丁·埃文斯开发了一种在子宫中培养小鼠胚胎的新技术，可以从这些胚胎中获得胚胎干细胞的衍生物。</div>   
        </div> <p></p><p>
 </p><ul>
  <li>1981年:胚胎干细胞首先由两个独立的研究小组从小鼠胚胎中获得。剑桥大学遗传学系的马丁·埃文斯和马修·考夫曼于7月首次发表论文表明，他们开发了一种在子宫中培养小鼠胚胎的新技术，这种新技术可以增加细胞数量，从而从这些胚胎中获得胚胎干细胞的衍生物。 加州大学旧金山分校解剖学系的盖尔·马丁在12月发表了她的论文，并创造了“胚胎干细胞”一词。 她表明胚胎可以在体外培养，同时胚胎干细胞可以从这些胚胎中获得。</li>
  <li>1989年:马里奥·卡佩奇、马丁·伊文斯和奥利弗·史密西斯发表了他们的研究，详细阐述了他们对胚胎干细胞的分离和基因改造，创造了第一只“敲除小鼠”。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_48" class="kx_ref">[48]</a></sup> 在创造“敲除小鼠”的过程中，这篇文章为科学家提供了一种全新的研究疾病的方法。</li>
  <li>1998年:威斯康星大学麦迪逊分校的一个团队(詹姆斯·汤姆森、约瑟夫·伊茨科维奇-埃尔多、桑德·夏皮罗、米歇尔·瓦肯茨、詹妮弗·j·斯威吉尔、维维安·马歇尔和杰弗里·琼斯)发表了一篇题为《源自人类囊胚的胚胎干细胞系》的论文。这项研究背后的研究人员不仅创造了第一批胚胎干细胞，而且认识到它们的多能性以及自我更新的能力。这篇论文的摘要指出了这一发现在发育生物学和药物发掘领域的重要意义。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_49" class="kx_ref">[49]</a></sup></li>
  <li>2001年:乔治·布什总统允许联邦资金支持大约60个——当时已经存在的——胚胎干细胞系的研究。鉴于布什允许研究的有限干细胞系已经建立，这项法律支持的胚胎干细胞研究不会引起任何伦理问题，而在联邦预算建立新的干细胞系则可能会引发伦理问题。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_50" class="kx_ref">[50]</a></sup></li>
  <li>2006年:日本科学家山中伸弥和高桥知利发表了一篇描述从成年小鼠成纤维细胞培养物中诱导多能干细胞的论文。诱导多能干细胞（iPSCs）是一个巨大的发现，因为它们似乎与胚胎干细胞一致，而且可以在不引发同样道德争议的情况下使用。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_51" class="kx_ref">[51]</a></sup></li>
  <li>2009年1月:美国食品和药物管理局(FDA)批准Geron公司对其人类胚胎干细胞衍生的对脊髓损伤治疗的第一阶段试验。这项声明得到科学界的热烈欢迎，但也受到干细胞反对者的警惕。然而，治疗细胞来源于乔治·布什的胚胎干细胞政策下批准的细胞系。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_52" class="kx_ref">[52]</a></sup></li>
  <li>2009年3月:巴拉克·奥巴马总统签署了第13505号行政命令，取消了前总统政府对联邦资助人类干细胞的限制。这将使国家卫生研究院（NIH）能够为人类胚胎干细胞研究提供资助。该文件还指出，国家卫生研究院必须在命令签署后的120天内提供修订后的联邦资助指南。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_53" class="kx_ref">[53]</a></sup></li>
 </ul><p></p></div></div><div id="par_14995394995945987"><h2 class="title">5 胚胎干细胞的来源和培养的技术和条件<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>5.1 <span>源自人类</span></h3><p></p><p>体外受精会产生多个胚胎。这会产生一些过剩的胚胎不用于临床或不适合植入患者体内，因此可以在征得供体同意的情况下可能获得捐赠。人类胚胎干细胞可以从这些捐赠的胚胎中获得，或者还可以使用患者的细胞和捐赠的卵子从克隆的胚胎中提取。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_54" class="kx_ref">[54]</a></sup> 胚胎囊胚期的内细胞团(感兴趣的细胞)与滋养层细胞分离，滋养层细胞将来分化为胚外组织。从免疫外科来说，通过抗体结合到滋养层细胞并且被另一种溶液去除，与此同时进行机械解剖以实现（内细胞团的）分离。获得的内部细胞团细胞被接种到提供支持的细胞上。内部细胞团细胞附着在一起并进一步扩张形成未分化的人胚胎细胞系。每天需给这些细胞提供养分，而且每四至七天需通过酶解或机械分离一次。为了发生分化，将人胚胎干细胞系从支持细胞中取出以形成胚状体，然后与含有必要信号分子的血清共培养，或者移植到三维支架中以产生。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_55" class="kx_ref">[55]</a></sup> </p><p></p><h3>5.2 <span>源自其他动物</span></h3><p></p><p>胚胎干细胞来源于早期胚胎的内细胞团，这些细胞团是从供体雌性动物身上获得的。马丁·埃文斯和马修·考夫曼报道了一种延迟胚胎植入的技术，该技术允许内细胞团数量增加。这个过程包括摘除捐献者母亲的卵巢，给她注射黄体酮以改变激素环境，从而使胚胎在子宫中保持自由。在子宫内培养4-6天后，胚胎即被收获并在体外培养至内细胞团形成“卵圆筒状结构”，此时内细胞团分离成单细胞，并铺在用丝裂霉素c处理的成纤维细胞上(以防止成纤维细胞进行有丝分裂)。克隆的细胞系是由单个细胞生长而成的。埃文斯和考夫曼表明，从这些培养物中生长出来的细胞可以形成畸胎瘤和胚状体，以及可以在体外分化，以上结果表明这些细胞具有多能性。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_56" class="kx_ref">[56]</a></sup> </p><p>盖尔·马丁以不同的方式获得和培养她的胚胎干细胞。她从交配后大约76小时的捐献者母亲身上取出胚胎，并在含血清的培养基中培养过夜。第二天，她通过显微外科手术从晚期胚泡剥离出内细胞团。提取的内细胞团在含有血清的培养基并用丝裂霉素c处理的成纤维细胞上培养，并根据胚胎干细胞的状态作调节。大约一周后，细胞系形成。这些细胞在培养物中生长并表现出多能特性，如形成畸胎瘤、进行体外分化和形成胚状体的能力。马丁称这些细胞为胚胎干细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_56" class="kx_ref">[56]</a></sup> </p><p>目前已知饲养细胞提供的白血病抑制因子（LIF）和血清中提供的骨形态发生蛋白（BMPs）对于阻止胚胎干细胞的分化是必需的。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_56" class="kx_ref">[56]</a></sup><sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_57" class="kx_ref">[57]</a></sup> 这些因子对胚胎干细胞的衍生效率极其重要。此外，研究表明不同的小鼠品系具有不同的分离胚胎干细胞的效率。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_58" class="kx_ref">[58]</a></sup> 小鼠胚胎干细胞目前的用途包括制备转基因小鼠，包括“基因敲除小鼠”。对于人类治疗，需要具有患者特异性多能细胞。人类胚胎干细胞的生成产生更加困难，并面临伦理问题。因此，除了人类胚胎干细胞研究之外，许多团队更关注于诱导多能干细胞(iPS cells)的产生。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_59" class="kx_ref">[59]</a></sup> </p><p></p><h3>5.3 <span>新细胞系来源的潜在方法</span></h3><p></p><p>2006年8月23日，科学类杂志《自然》在线发表了罗伯特·兰扎博士(马萨诸塞州伍斯特市高级细胞技术医学主任)的一篇短文，声称他的团队找到了一种在不破坏真正胚胎的情况下提取胚胎干细胞的方法。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_60" class="kx_ref">[60]</a></sup> 这一技术成就将有可能使科学家们能够利用美国公共资金研究新的胚胎干细胞系，因为当时美国联邦资金仅限于利用2001年8月以前获得的胚胎干细胞系进行研究。直到2009年3月，限制被解除。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_61" class="kx_ref">[61]</a></sup> </p><p></p><h3>5.4 <span>诱导多能干细胞</span></h3><p></p><p>iPSC技术是由日本京都的山中伸弥实验室首创的，该实验室在2006年表明向成体细胞中导入四种编码特定转录因子的基因可以将成体细胞转化为多能干细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_62" class="kx_ref">[62]</a></sup> 他与约翰·古登爵士一起获得了2012年诺贝尔奖，“因为他们发现成熟细胞可以被重编程而具有多能性。” <sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_63" class="kx_ref">[63]</a></sup> </p><p>2007年，研究表明，通过将三种基因(<i>Oct4</i>、<i>Sox2</i>和<i>Klf4</i>)导入已分化的细胞，可以产生与胚胎干细胞高度相似的多能干细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_64" class="kx_ref">[64]</a></sup> 这些基因的导入可以将已分化的细胞“重编程”为多能干细胞，从而可以在没有胚胎的情况下产生多能干细胞。因为关于胚胎干细胞的伦理问题通常是关于它们从终止的胚胎中衍生出来的，所以人们相信对这些重编程的“诱导多能干细胞”(iPS细胞)可能存在更少的争议。人类和小鼠细胞都可以通过这种方法重新编程，在无需胚胎的情况下产生人类多能干细胞和小鼠多能干细胞。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_65" class="kx_ref">[65]</a></sup> </p><p>这可以产生可能用于细胞替代治疗的患者特异性胚胎干细胞系。此外，这将允许从患有各种遗传疾病的患者中产生胚胎干细胞系，并将为研究这些疾病提供宝贵的模型。</p><p>然而，正如《科学》杂志2007年12月6日在线报道的那样，作为诱导多能干细胞(iPS)细胞技术能够接连不断地引起新疗法的第一个标志，马萨诸塞州剑桥怀特黑德生物医学研究所的鲁道夫·杰尼斯奇(Rudolf Jaenisch)领导的一个研究小组使用该技术来治疗小鼠镰状细胞性贫血。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_66" class="kx_ref">[66]</a></sup><sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_67" class="kx_ref">[67]</a></sup> </p><p>2008年1月16日，一家总部设在加州的斯坦玛根公司宣布，他们已经从取自成年人的单一皮肤细胞中创造了第一个成熟的人类克隆胚胎。这些胚胎可以为与胚胎干细胞匹配成功的患者采集。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_68" class="kx_ref">[68]</a></sup> </p><p></p><h3>5.5 <span>细胞培养中的试剂污染</span></h3><p></p><p>2005年1月24日，《自然医学》在线发表的一项研究指出，可用于联邦资助研究的人类胚胎干细胞被用于培养细胞的培养基中的非人类分子污染。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_69" class="kx_ref">[69]</a></sup> 使用小鼠细胞和其他动物细胞来维持具有高度分裂活性的干细胞的多能性是一种常见的技术。据加利福尼亚大学圣地亚哥分校的科学家称，他们发现生长培养基中的非人类唾液酸会降低胚胎干细胞在人类中的潜在用途。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_70" class="kx_ref">[70]</a></sup> </p><p>然而，2005年3月8日在线发表在《柳叶刀》医学杂志上的一项研究详细介绍了一种新的干细胞系，这种干细胞系是在完全无细胞和无血清的条件下从人类胚胎中获得的。在超过6个月的未分化增殖后，这些细胞在体外和畸胎瘤中显示出形成所有三个胚胎胚层衍生细胞的潜力。利用已建立的干细胞系，这些特性同样可以成功维持(超过30代)。<sup><a href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/d10536.htm#quote_71" class="kx_ref">[71]</a></sup> </p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thomson; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM (1998). "Blastocysts Embryonic Stem Cell Lines Derived from Human". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"NIH Stem Cell Basics. What are embryonic stem cells?"..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Baldwing A (2009). "Morality and human embryo research. Introduction to the Talking Point on morality and human embryo research". EMBO Reports. 10 (4): 299–300. doi:10.1038/embor.2009.37. PMC 2672902. PMID 19337297..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Nakaya, Andrea C. (August 1, 2011). Biomedical ethics. San Diego, CA: ReferencePoint Press. p. 96. ISBN 978-1601521576..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Introduction: What are stem cells, and why are they important?". National Institutes of Health. Retrieved 28 October 2018..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Carla A Herberts; Marcel SG Kwa; Harm PH Hermsen (2011). "Risk factors in the development of stem cell therapy". Journal of Translational Medicine. 9 (29): 29. doi:10.1186/1479-5876-9-29. PMC 3070641. PMID 21418664..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thomson, J. A.; Itskovitz-Eldor, J; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. S.; Jones, J. M. (1998). "Embryonic Stem Cell Lines Derived from Human Blastocysts". Science. 282 (5391): 1145–7. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ying; Nichols, J; Chambers, I; Smith, A (2003). "BMP Induction of Id Proteins Suppresses Differentiation and Sustains Embryonic Stem Cell Self-Renewal in Collaboration with STAT3". Cell. 115 (3): 281–292. doi:10.1016/S0092-8674(03)00847-X. PMID 14636556..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Template:Cite PMID: 25288119.</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">PMID 26889666（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充.</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">PMID 15703208（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充.</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">PMID 19968627（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充.</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">PMID 19139263（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充.</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Mahla, Ranjeet (July 19, 2016). "Stem Cell Applications in Regenerative Medicine and Disease Therapeutics". International Journal of Cell Biology. 2016: 6940283. doi:10.1155/2016/6940283. PMC 4969512. PMID 27516776..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Levenberg, S. (2002). "Endothelial cells derived from human embryonic stem cells". Proceedings of the National Academy of Sciences. 99 (7): 4391–4396. Bibcode:2002PNAS...99.4391L. doi:10.1073/pnas.032074999. PMC 123658. PMID 11917100..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Davila, JC; Cezar, GG; Thiede, M; Strom, S; Miki, T; Trosko, J (2004). "Use and application of stem cells in toxicology". Toxicological Sciences. 79 (2): 214–23. doi:10.1093/toxsci/kfh100. PMID 15014205..</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Siu, CW; Moore, JC; Li, RA (2007). "Human embryonic stem cell-derived cardiomyocytes for heart therapies". Cardiovascular &amp; Hematological Disorders Drug Targets. 7 (2): 145–52. doi:10.2174/187152907780830851. PMID 17584049..</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Perrier, A. L. (2004). "Derivation of midbrain dopamine neurons from human embryonic stem cells". Proceedings of the National Academy of Sciences. 101 (34): 12543–12548. Bibcode:2004PNAS..10112543P. doi:10.1073/pnas.0404700101. PMC 515094. PMID 15310843..</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Parish, CL; Arenas, E (2007). "Stem-cell-based strategies for the treatment of Parkinson's disease". Neuro-Degenerative Diseases. 4 (4): 339–47. doi:10.1159/000101892. PMID 17627139..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Waese, EY; Kandel, RA; Stanford, WL (2008). "Application of stem cells in bone repair". Skeletal Radiology. 37 (7): 601–8. doi:10.1007/s00256-007-0438-8. PMID 18193216..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">d'Amour, KA; Bang, AG; Eliazer, S; Kelly, OG; Agulnick, AD; Smart, NG; Moorman, MA; Kroon, E; Carpenter, MK; Baetge, EE (2006). "Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells". Nature Biotechnology. 24 (11): 1392–401. doi:10.1038/nbt1259. PMID 17053790..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Colen, B.D. (9 October 2014) Giant leap against diabetes The Harvard Gazette, Retrieved 24 November 2014.</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Menasché, Phillip; Vanneaux, Valérie; Fabreguettes, Jean-Roch; Bel, Alain; Tosca, Lucie; Garcia, Sylvie (21 March 2015). "Towards a clinical use of human embryonic stem cell derived-cardiac progenitors: a translational experience". European Heart Journal. 36 (12): 743–750. doi:10.1093/eurheartj/ehu192. PMID 24835485..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jensen, J; Hyllner, J; Björquist, P (2009). "Human embryonic stem cell technologies and drug discovery". Journal of Cellular Physiology. 219 (3): 513–9. doi:10.1002/jcp.21732. PMID 19277978..</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Söderdahl, T; Küppers-Munther, B; Heins, N; Edsbagge, J; Björquist, P; Cotgreave, I; Jernström, B (2007). "Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells". Toxicology in Vitro. 21 (5): 929–37. doi:10.1016/j.tiv.2007.01.021. PMID 17346923..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Dr. Yury Verlinsky, 1943–2009: Expert in reproductive technology" Chicago Tribune, July 20, 2009.</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Mao Z, Bozzella M, Seluanov A, Gorbunova V (September 2008). "DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells". Cell Cycle. 7 (18): 2902–6. doi:10.4161/cc.7.18.6679. PMC 2754209. PMID 18769152..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tichy ED, Pillai R, Deng L, et al. (November 2010). "Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double-strand DNA breaks". Stem Cells Dev. 19 (11): 1699–711. doi:10.1089/scd.2010.0058. PMC 3128311. PMID 20446816..</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hong Y, Stambrook PJ (October 2004). "Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation". Proc. Natl. Acad. Sci. U.S.A. 101 (40): 14443–8. Bibcode:2004PNAS..10114443H. doi:10.1073/pnas.0401346101. PMC 521944. PMID 15452351..</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Aladjem MI, Spike BT, Rodewald LW, et al. (January 1998). "ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage". Curr. Biol. 8 (3): 145–55. doi:10.1016/S0960-9822(98)70061-2. PMID 9443911..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bernstein C, Bernstein H, Payne CM, Garewal H (June 2002). "DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis". Mutat. Res. 511 (2): 145–78. doi:10.1016/S1383-5742(02)00009-1. PMID 12052432..</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ (March 2002). "Embryonic stem cells and somatic cells differ in mutation frequency and type". Proc. Natl. Acad. Sci. U.S.A. 99 (6): 3586–90. Bibcode:2002PNAS...99.3586C. doi:10.1073/pnas.062527199. PMC 122567. PMID 11891338..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"FDA approves human embryonic stem cell study - CNN.com". January 23, 2009. Retrieved May 1, 2010..</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Keirstead HS, Nistor G, Bernal G, et al. (2005). "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". J. Neurosci. 25 (19): 4694–705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Reinberg, Steven (2009-01-23) FDA OKs 1st Embryonic Stem Cell Trial. The Washington Post.</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Geron comments on FDA hold on spinal cord injury trial. geron.com (August 27, 2009).</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Vergano, Dan (11 October 2010). "Embryonic stem cells used on patient for first time". USA Today. Retrieved 12 October 2010..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Brown, Eryn (November 15, 2011). "Geron exits stem cell research". LA Times. Retrieved 2011-11-15..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program". iPScell.com. October 1, 2013..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">California Institute of Regenerative Medicine. BioTime, Inc..</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Knoepfler, Paul S. (2009). "Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine". Stem Cells. 27 (5): 1050–6. doi:10.1002/stem.37. PMC 2733374. PMID 19415771..</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Varlakhanova, Natalia V.; Cotterman, Rebecca F.; Devries, Wilhelmine N.; Morgan, Judy; Donahue, Leah Rae; Murray, Stephen; Knowles, Barbara B.; Knoepfler, Paul S. (2010). "Myc maintains embryonic stem cell pluripotency and self-renewal". Differentiation. 80 (1): 9–19. doi:10.1016/j.diff.2010.05.001. PMC 2916696. PMID 20537458..</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wernig, Marius; Meissner, Alexander; Cassady, John P; Jaenisch, Rudolf (2008). "C-Myc is Dispensable for Direct Reprogramming of Mouse Fibroblasts". Cell Stem Cell. 2 (1): 10–2. doi:10.1016/j.stem.2007.12.001. PMID 18371415..</span></p></li><li id="quote_44"><span class="references-num">[44]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">King, Nancy; Perrin, Jacob (July 7, 2014). "Ethical issues in stem cell research and therapy". Stem Cell Research and Therapy. 5 (4): 85. doi:10.1186/scrt474. PMC 4097842..</span></p></li><li id="quote_45"><span class="references-num">[45]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kleinsmith LJ, Pierce GB Jr (1964). "Multipotentiality of Single Embryoncal Carcinoma Cells". Cancer Res. 24: 1544–51. PMID 14234000..</span></p></li><li id="quote_46"><span class="references-num">[46]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Andrews P, Matin M, Bahrami A, Damjanov I, Gokhale P, Draper J (2005). "Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin" (PDF). Biochem Soc Trans. 33 (Pt 6): 1526–30. doi:10.1042/BST20051526. PMID 16246161..</span></p></li><li id="quote_47"><span class="references-num">[47]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Martin GR (1980). "Teratocarcinomas and mammalian embryogenesis". Science. 209 (4458): 768–76. Bibcode:1980Sci...209..768M. doi:10.1126/science.6250214. PMID 6250214..</span></p></li><li id="quote_48"><span class="references-num">[48]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The 2007 Nobel Prize in Physiology or Medicine - Advanced Information". Nobel Prize. Nobel Media..</span></p></li><li id="quote_49"><span class="references-num">[49]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thompson, James A.; Itskovitz-Eldor, Joseph; Shapiro, Sander S.; Waknitz, Michelle A.; Swiergiel, Jennifer J.; Marshall, Vivienne S.; Jones, Jeffrey M. (6 November 1998). "Embryonic Stem Cell Lines Derived From Human Blastocyst". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145..</span></p></li><li id="quote_50"><span class="references-num">[50]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"President George W. Bush's address on stem cell research". CNN Inside Politics. CNN. Aug 9, 2001..</span></p></li><li id="quote_51"><span class="references-num">[51]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Yamanaka, Shinya; Takahashi, Kazutoshi (25 Aug 2006). "Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors". Cell. 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174..</span></p></li><li id="quote_52"><span class="references-num">[52]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wadman, Meredith (27 January 2009). "Stem cells ready for primetime". Nature. Nature. 457 (7229): 516. doi:10.1038/457516a. PMID 19177087..</span></p></li><li id="quote_53"><span class="references-num">[53]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Executive Order 13505—Removing Barriers To Responsible Scientific Research Involving Human Stem Cells" (PDF). Federal Register: Presidential Documents. 74 (46). 11 March 2009..</span></p></li><li id="quote_54"><span class="references-num">[54]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Mountford, JC (2008). "Human embryonic stem cells: origins, characteristics and potential for regenerative therapy". Transfus Med. 18 (1): 1–12. doi:10.1111/j.1365-3148.2007.00807.x. PMID 18279188..</span></p></li><li id="quote_55"><span class="references-num">[55]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998). "Embryonic stem cell lines derived from human blastocysts". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556..</span></p></li><li id="quote_56"><span class="references-num">[56]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Evans M, Kaufman M (1981). "Establishment in culture of pluripotent cells from mouse embryos". Nature. 292 (5819): 154–6. Bibcode:1981Natur.292..154E. doi:10.1038/292154a0. PMID 7242681..</span></p></li><li id="quote_57"><span class="references-num">[57]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA, Gough NM (1988). "Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells". Nature. 336 (6200): 684–687. Bibcode:1988Natur.336..684W. doi:10.1038/336684a0. PMID 3143916..</span></p></li><li id="quote_58"><span class="references-num">[58]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ledermann B, Bürki K (1991). "Establishment of a germ-line competent C57BL/6 embryonic stem cell line". Exp Cell Res. 197 (2): 254–258. doi:10.1016/0014-4827(91)90430-3. PMID 1959560..</span></p></li><li id="quote_59"><span class="references-num">[59]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. PMID 18035408..</span></p></li><li id="quote_60"><span class="references-num">[60]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R (2006). "Human embryonic stem cell lines derived from single blastomeres". Nature. 444 (7118): 481–5. Bibcode:2006Natur.444..481K. doi:10.1038/nature05142. PMID 16929302..</span></p></li><li id="quote_61"><span class="references-num">[61]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">US scientists relieved as Obama lifts ban on stem cell research, The Guardian, 10 March 2009.</span></p></li><li id="quote_62"><span class="references-num">[62]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Takahashi, K; Yamanaka, S (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell. 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174..</span></p></li><li id="quote_63"><span class="references-num">[63]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The Nobel Prize in Physiology or Medicine – 2012 Press Release". Nobel Media AB. 8 October 2012..</span></p></li><li id="quote_64"><span class="references-num">[64]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wernig, Marius; Meissner, Alexander; Foreman, Ruth; Brambrink, Tobias; Ku, Manching; Hochedlinger, Konrad; Bernstein, Bradley E.; Jaenisch, Rudolf (2007-07-19). "In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state". Nature. 448 (7151): 318–324. Bibcode:2007Natur.448..318W. doi:10.1038/nature05944. ISSN 1476-4687. PMID 17554336..</span></p></li><li id="quote_65"><span class="references-num">[65]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Embryonic stem cells made without embryos". Reuters. 2007-11-21..</span></p></li><li id="quote_66"><span class="references-num">[66]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Weiss, Rick (2007-12-07). "Scientists Cure Mice Of Sickle Cell Using Stem Cell Technique: New Approach Is From Skin, Not Embryos". The Washington Post. pp. A02..</span></p></li><li id="quote_67"><span class="references-num">[67]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hanna, J.; Wernig, M.; Markoulaki, S.; Sun, C.-W.; Meissner, A.; Cassady, J. P.; Beard, C.; Brambrink, T.; Wu, L.-C.; Townes, T. M.; Jaenisch, R. (2007). "Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin". Science. 318 (5858): 1920–3. Bibcode:2007Sci...318.1920H. doi:10.1126/science.1152092. PMID 18063756..</span></p></li><li id="quote_68"><span class="references-num">[68]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Helen Briggs (2008-01-17). "US team makes embryo clone of men". BBC. pp. A01..</span></p></li><li id="quote_69"><span class="references-num">[69]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ebert, Jessica (24 January 2005). "Human stem cells trigger immune attack". Nature News. London: Nature Publishing Group. doi:10.1038/news050124-1. Archived from the original on 2010-09-24. Retrieved 2009-02-27..</span></p></li><li id="quote_70"><span class="references-num">[70]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Martin MJ, Muotri A, Gage F, Varki A (2005). "Human embryonic stem cells express an immunogenic nonhuman sialic acid". Nat. Med. 11 (2): 228–32. doi:10.1038/nm1181. PMID 15685172..</span></p></li><li id="quote_71"><span class="references-num">[71]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Klimanskaya I, Chung Y, Meisner L, Johnson J, West MD, Lanza R (2005). "Human embryonic stem cells derived without feeder cells". Lancet. 365 (9471): 1636–41. doi:10.1016/S0140-6736(05)66473-2. PMID 15885296..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->6714</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221028211915/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221028211915/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221028211915/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221028211915/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"10536","versionId":"54114251517780235","title":"胚胎干细胞","subtitle":"","abstracts":{"paragraphId":"54114251534557443","title":"摘要","versionId":"54114251517780236","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p><b>胚胎干细胞（Embryonic stem cells,ES细胞或ESCs）</b>是来源于囊胚内细胞团的多能干细胞，而囊胚是胚胎植入前早期的一个阶段。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 人类胚胎在受精后4-5天到达囊胚期，此时的胚胎由50-150个细胞组成。分离胚结或内细胞团（ICM）会导致囊胚的破坏，这一过程会引发伦理问题，包括植入前阶段的胚胎是否应具有与植入后发育阶段的胚胎相同的道德考虑。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup><sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> 研究人员目前非常关注胚胎干细胞的治疗潜力，因为临床应用是许多实验室的目标。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>潜在用途包括治疗糖尿病和心脏病。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> 这些细胞正被研究用于临床治疗、遗传疾病模型和细胞/脱氧核糖核酸（DNA）修复。然而，研究和临床过程中的副作用，如肿瘤和免疫排斥反应也有报道。<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12985?width=231&height=174&titlename=%E7%BB%86%E8%83%9E%E5%9F%B9%E5%85%BB%E4%B8%AD%E7%9A%84%E4%BA%BA%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E&w=300&h=225","url":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12985","rw":300,"rh":225,"title":"细胞培养中的人胚胎干细胞","alt":null,"width":231,"height":174}],"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"54114251517780243","title":"基本信息","versionId":"54114251517780237","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":3,"content":"","pics":null,"card":{"cardItems":[{"key":"外文名","value":"embryonic stem cell"},{"key":"简称","value":"ES、EK细胞"},{"key":"最早","value":"1981年"}]},"references":[],"versionCount":0},"categories":[{"id":4,"name":"生物学","parents":[]}],"creator":{"uid":76032035,"name":"sunny","pic":"https://web.archive.org/web/20221028211915/https://cache.soso.com/qlogo/g?b=oidb&k=CtdtTt12xWnHYHSFlIXyKw&s=100&t=1556563002","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":1568622679,"editor":{"uid":76033348,"name":"廖志刚","pic":"https://web.archive.org/web/20221028211915/https://cache.soso.com/qlogo/g?b=oidb&k=VK4KcKvSwAcZWWvibMYwrqw&s=100&t=1483307853","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":164,"partnerIdCreateTime":1595844887,"partnerIdPoped":false},"editTime":1576233951,"state":1,"versionCount":2,"upNum":4,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12985?width=231&height=174&titlename=%E7%BB%86%E8%83%9E%E5%9F%B9%E5%85%BB%E4%B8%AD%E7%9A%84%E4%BA%BA%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E&w=300&h=225","url":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12985","rw":300,"rh":225,"title":"细胞培养中的人胚胎干细胞","alt":null,"width":231,"height":174},{"originalUrl":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12987?w=300&h=199&titlename=%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E%E7%9A%84%E8%BD%AC%E5%BD%95%E7%BB%84","url":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12987","rw":300,"rh":199,"title":"胚胎干细胞的转录组","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12988?w=300&h=300&titlename=%E8%83%9A%E7%8A%B6%E4%BD%93%E5%BD%A2%E6%88%90%E5%90%8E24%E5%B0%8F%E6%97%B6","url":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12988","rw":300,"rh":300,"title":"胚状体形成后24小时","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12989?w=140&h=210&titlename=%E9%A9%AC%E4%B8%81%C2%B7%E5%9F%83%E6%96%87%E6%96%AF%E5%BC%80%E5%8F%91%E4%BA%86%E4%B8%80%E7%A7%8D%E5%9C%A8%E5%AD%90%E5%AE%AB%E4%B8%AD%E5%9F%B9%E5%85%BB%E5%B0%8F%E9%BC%A0%E8%83%9A%E8%83%8E%E7%9A%84%E6%96%B0%E6%8A%80%E6%9C%AF%EF%BC%8C%E5%8F%AF%E4%BB%A5%E4%BB%8E%E8%BF%99%E4%BA%9B%E8%83%9A%E8%83%8E%E4%B8%AD%E8%8E%B7%E5%BE%97%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E%E7%9A%84%E8%A1%8D%E7%94%9F%E7%89%A9%E3%80%82","url":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12989","rw":140,"rh":210,"title":"马丁·埃文斯开发了一种在子宫中培养小鼠胚胎的新技术，可以从这些胚胎中获得胚胎干细胞的衍生物。","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"特性","paragraphId":"14995394979168780","subCatalogs":[{"level":2,"title":"多能性","paragraphId":"14995394979168780","subCatalogs":null},{"level":2,"title":"自我更新","paragraphId":"14995394979168780","subCatalogs":null},{"level":2,"title":"增殖","paragraphId":"14995394979168780","subCatalogs":null},{"level":2,"title":"用途","paragraphId":"14995394979168780","subCatalogs":null}]},{"level":1,"title":"应用","paragraphId":"14995394979168781","subCatalogs":[{"level":2,"title":"细胞替代疗法","paragraphId":"14995394979168781","subCatalogs":null},{"level":2,"title":"临床潜力","paragraphId":"14995394979168781","subCatalogs":null},{"level":2,"title":"药物发现","paragraphId":"14995394979168781","subCatalogs":null},{"level":2,"title":"遗传疾病模型","paragraphId":"14995394979168781","subCatalogs":null},{"level":2,"title":"DNA损伤修复<b>（脱氧核糖核酸损伤修复）</b>","paragraphId":"14995394979168781","subCatalogs":null},{"level":2,"title":"临床试验","paragraphId":"14995394979168781","subCatalogs":null}]},{"level":1,"title":"关注和争议","paragraphId":"14995394979168782","subCatalogs":[{"level":2,"title":"<b>负面效应</b>","paragraphId":"14995394979168782","subCatalogs":null},{"level":2,"title":"伦理争论","paragraphId":"14995394979168782","subCatalogs":null}]},{"level":1,"title":"历史","paragraphId":"14995394979168783","subCatalogs":null},{"level":1,"title":"胚胎干细胞的来源和培养的技术和条件","paragraphId":"14995394995945987","subCatalogs":[{"level":2,"title":"源自人类","paragraphId":"14995394995945987","subCatalogs":null},{"level":2,"title":"<b>源</b>自其他动物","paragraphId":"14995394995945987","subCatalogs":null},{"level":2,"title":"新<b>细胞系来源的潜在方法</b>","paragraphId":"14995394995945987","subCatalogs":null},{"level":2,"title":"诱导多能干细胞","paragraphId":"14995394995945987","subCatalogs":null},{"level":2,"title":"<b>细胞培养中的试剂污染</b>","paragraphId":"14995394995945987","subCatalogs":null}]},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14995394979168780","title":"特性","versionId":"54114251517780238","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right currentPic\" img_height=\"199\" img_width=\"300\" titlename=\"胚胎干细胞的转录组\" data-src=\"https://img04.sogoucdn.com/app/a/200698/sogou_science_12987\"> </p><p>胚胎干细胞(ESCs)来源于早期哺乳动物胚胎的囊胚阶段，其特点是能够分化成任何类型胚胎细胞，并具有自我更新的能力。正是这些特性使它们在科学和医学领域具有价值。胚胎干细胞具有正常的核型，保持高端粒酶活性，并表现出显著的长期增殖潜力。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p><p></p><h3>多能性</h3><p></p><p>内细胞团的胚胎干细胞具有多能性，这意味着它们能够分化产生原始外胚层，在原肠胚形成过程中最终分化为三个初级胚层的所有衍生物：外胚层、内胚层和中胚层。这些胚层在成人体内生成220多种类型细胞中的每一种。当提供适当的信号时，胚胎干细胞最初形成前体细胞，随后分化成所需的细胞类型。多能性将胚胎干细胞与成体干细胞区分开来，成体干细胞是专能性的，只能产生有限数量的细胞类型。</p><p></p><h3>自我更新</h3><p></p><p>在特定条件下，胚胎干细胞能够在未分化状态下无限期自我更新。自我更新的条件是必须防止细胞聚集并维持一个使其处于不分化状态的环境。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup> 通常这是在实验室用含有血清和白血病抑制因子的培养基或含有两种抑制药物(甲乙酮抑制剂PD03259010和GSK-3抑制剂CHIR99021，“2i”)的无血清培养基来实现的。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup> </p><p></p><h3>增殖</h3><p></p><p>由于细胞周期中G1期缩短，胚胎干细胞分裂非常频繁。快速的细胞分裂使细胞数量快速增加，而不是细胞大小增加，这对早期胚胎发育很重要。在胚胎干细胞中，参与细胞周期G1/S转换的细胞周期蛋白A和细胞周期蛋白E总是高水平表达。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup> 促进细胞周期进程的细胞周期蛋白依赖性激酶，如CDK2，部分原因是由于其抑制因子的下调而过度激活。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup> 视网膜母细胞瘤蛋白抑制转录因子E2F，直到细胞准备进入S期，但在胚胎干细胞中视网膜母细胞瘤蛋白被过度磷酸化而失活，导致增殖基因的持续表达。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup> 这些变化导致细胞分裂周期加快。尽管缩短的G1期与胚胎干细胞的多能性[12]维持有关，但在含两种抑制药物的无血清条件下生长的胚胎干细胞确实表达低磷酸化活性的视网膜母细胞瘤蛋白，并具有延长的G1期<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup> <sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup>。尽管与含血清培养基中生长的胚胎干细胞相比，细胞周期有所不同，但这些细胞具有相似的多能性，多能因子Oct4和Nanog在转录调节胚胎干细胞细胞周期中发挥作用。</p><p></p><h3>用途</h3><p></p><p>由于胚胎干细胞的可塑性和潜在的无限自我更新能力，胚胎干细胞疗法已被提议用于损伤或疾病后的再生医学和组织置换。多能干细胞在治疗多种不同疾病方面显示出前景，包括但不限于：脊髓损伤、年龄相关性黄斑变性、糖尿病、神经退行性疾病(如帕金森病)、艾滋病等。<sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup> 除了在再生医学方面的潜力外，胚胎干细胞还提供了组织或器官的一种可能的替代来源，这是解决供体短缺困境的一种办法。但是围绕这一点有一些伦理争议(见下面的伦理辩论部分)。除了这些用途之外，胚胎干细胞还可以用于人类早期发育、某些遗传疾病和体外毒理学试验的研究。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12987?w=300&h=199&titlename=%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E%E7%9A%84%E8%BD%AC%E5%BD%95%E7%BB%84","url":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12987","rw":300,"rh":199,"title":"胚胎干细胞的转录组","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14995394979168781","title":"应用","versionId":"54114251517780239","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>根据2002年在《美国科学院院刊》（PNAS）上发表的一篇文章，“人类胚胎干细胞具有分化成各种细胞类型的潜力”，因此，可以用作移植或组织工程的细胞来源。”<sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup> </p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"300\" img_width=\"300\" titlename=\"胚状体形成后24小时\" data-src=\"https://img01.sogoucdn.com/app/a/200698/sogou_science_12988\"> </p><p>然而，胚胎干细胞的应用不局限于细胞/组织工程。</p><p></p><h3>细胞替代疗法</h3><p></p><p>目前的研究集中在将胚胎干细胞分化成多种细胞类型，最终用作细胞替代疗法（CRTs）。一些已经或正在开发的细胞类型包括心肌细胞（CM）、神经元、肝细胞、骨髓细胞、胰岛细胞和内皮细胞。<sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup> 然而，从胚胎干细胞中获得这种细胞类型并非没有障碍，因此目前的研究侧重于克服这些障碍。例如，研究人员正在研究将胚胎干细胞分化成组织特异性心肌细胞，以及根除它们与成人心肌细胞不同的不成熟的特性。<sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup> </p><p></p><h3>临床潜力</h3><p></p><p>\n </p><ul>\n  <li>研究人员已经将胚胎干细胞分化为产生多巴胺的细胞，希望这些神经元能够用于治疗帕金森氏病。<sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup><sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup></li>\n  <li>胚胎干细胞已经分化为自然杀伤细胞（NK）和骨组织。<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup></li>\n  <li>胚胎干细胞用于治疗糖尿病的替代治疗正在研究中。例如，达穆尔等人能够将胚胎干细胞分化为产生胰岛素的细胞，<sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup> 哈佛大学的研究人员能够从胚胎干细胞中产生大量胰岛β细胞。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup></li>\n  <li>发表在《欧洲心脏杂志》上的一篇文章描述了人类胚胎干细胞衍生心脏祖细胞的转化过程，并用于严重心力衰竭患者的临床试验。<sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup></li>\n </ul><p></p><p></p><h3>药物发现</h3><p></p><p>除了成为器官移植的重要替代物外，胚胎干细胞还被用于毒理学领域和细胞筛选，以发现可以开发为小分子药物的新化学实体（NCEs）。研究表明，胚胎干细胞衍生的心肌细胞在体外模型中得到验证，可以用于测试药物反应和预测毒性特征。<sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup> 胚胎干细胞衍生的心肌细胞已被证明对药物刺激有反应，因此可用于评估心脏毒性，如尖端扭转型室性心动过速。<sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup> </p><p>胚胎干细胞衍生的肝细胞也是有用的模型，可用于药物发现的临床前阶段。然而，将胚胎干细胞分化为肝细胞已被证明是具有挑战性的，这阻碍了测试药物代谢的能力。因此，目前的研究集中在建立具有稳定的第一和第二阶段酶活性的全功能性胚胎干细胞衍生肝细胞。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> </p><p></p><h3>遗传疾病模型</h3><p></p><p>几项新的研究已经开始探讨用胚胎干细胞模拟遗传疾病的概念。无论是通过基因操纵细胞，还是最近通过获得产前基因诊断（PGD）所鉴定的患病细胞系，利用干细胞模拟遗传疾病在某些方面已经获得成功。这种方法在研究诸如脆性X染色体综合征、囊性纤维化和其他没有可靠模型系统的遗传疾病方面可能非常有价值。</p><p>专攻胚胎和细胞遗传学(遗传细胞学)的俄裔美国医学研究者尤里·韦林斯基(YuryVerlinsky)开发了产前诊断的检测方法，比标准羊膜穿刺术早一个半月确定遗传和染色体异常。这种技术现在被许多孕妇和准父母所使用，特别是有遗传异常史的夫妇，或者超过35岁的妇女(患遗传相关疾病的风险更高)。此外，通过允许父母选择无遗传疾病的胚胎，他们有可能利用无疾病后代的细胞挽救已经患有类似疾病的兄弟姐妹的生命。<sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup> </p><p></p><h3>DNA损伤修复<b>（脱氧核糖核酸损伤修复）</b></h3><p></p><p>分化的体细胞和胚胎干细胞使用不同的策略来处理脱氧核糖核酸损伤。例如，人包皮成纤维细胞（一种体细胞）使用非同源末端连接(NHEJ)，这是一种容易出错的DNA修复过程，作为在所有细胞周期阶段修复双链断裂（DSBs）的主要途径。<sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup> 由于其易出错的性质，非同源末端连接修复途径倾向于在细胞克隆后代中产生突变。</p><p>胚胎干细胞使用不同的策略来应对双链断裂。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> 因为胚胎干细胞产生一个生物体包括生殖系细胞在内的所有细胞类型，所以在胚胎干细胞中因错误的DNA修复而产生的突变比在已分化的体细胞中产生的突变更为严重。因此，胚胎干细胞需要强有力的机制来准确修复受损的基因，如果修复失败，则移除那些未修复的细胞。因此，小鼠胚胎干细胞主要通过高保真同源重组修复(HRR)来修复DSBs。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> 这种类型的修复依赖于两条姐妹染色体的相互作用，这两条染色体在细胞周期的S期形成，在G2期同时存在。HRR可以通过利用来自另一条姐妹染色体的完整信息来精确修复其姐妹染色体中的DSB。处于细胞周期G1期的细胞(即中期/细胞分裂后但在下一轮复制前)每条染色体只有一个拷贝(即姐妹染色体不存在)。小鼠胚胎干细胞缺乏G1期检验点，在发生DNA损伤后不会经历细胞周期停滞。<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup> 更确切地说，它们启动细胞程序性死亡(凋亡)以应对DNA损伤。<sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup> 细胞凋亡可以作为一种故障安全策略，用于清除具有DNA损伤而未修复的细胞，以避免突变和癌症的发生。<sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> 与这一策略相一致的是，小鼠胚胎干细胞的突变频率比同基因型的小鼠体细胞低约100倍。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup> </p><p></p><h3>临床试验</h3><p></p><p>22009年1月23日，由人类胚胎干细胞衍生来的少突胶质细胞(大脑和脊髓的一种细胞类型)移植到脊髓损伤个体的第一阶段临床试验获得了美国食品和药物管理局(FDA)的批准，标志着世界上第一次人类胚胎干细胞的人类试验。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> 这项推动该领域科学进步的研究是由加州大学欧文分校的汉斯·凯尔斯特德及其同事完成的，并得到了由迈克尔·韦斯特博士创建的加利福尼亚州门罗公园Geron公司的支持。先前的一项实验表明，将人类胚胎干细胞定向诱导成少突胶质细胞后移植到脊髓受损7天的大鼠体内，之后其运动恢复状况有所改善。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> 第一阶段临床研究旨在招募大约8到10名截瘫患者，他们在试验开始前两周内受伤，因为必须在疤痕组织形成前注射细胞。研究人员强调，注射并不能完全治愈病人和恢复所有的活动能力。根据啮齿动物试验的结果，研究人员推测髓鞘的恢复和活动能力的增加可能会发生。第一次试验主要是为了测试该过程的安全性，如果一切顺利，希望它能促进人类更严重的伤残疾病的进一步研究。<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup> 该试验于2009年8月暂停，原因是美国食品和药物管理局担心在几个经过治疗的大鼠模型中发现少量微小囊肿，但该暂停于2010年7月30日被解除。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> </p><p>2010年10月，研究人员在亚特兰大的谢博德中心为第一个病人登记并实施了胚胎干细胞治疗。<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> 干细胞疗法的实施者Geron公司估计，干细胞的复制和GRNOPC1疗法成败的评估需要几个月的时间。</p><p>2011年11月，Geron公司宣布停止试验，并出于经济原因退出干细胞研究，但将继续监测现有患者，同时试图找到一个可以继续他们研究的合作伙伴。<sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> 2013年，首席执行官迈克尔·韦斯特(Michael D. West)博士领导的BioTime公司收购了Geron公司的所有干细胞资产，宣称打算重启Gerron公司基于胚胎干细胞的脊髓损伤研究临床试验。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup> </p><p>BioTime公司旗下的阿斯特里亚生物治疗公司(纽约证券交易所MKT: AST)获得了加州再生医学研究所(CIRM)授予的1430万美元战略合作伙伴奖，以重新启动世界上第一个基于胚胎干细胞的人类脊髓损伤临床试验。在加州公共基金的支持下，CIRM是世界上干细胞相关研究和开发的最大资助者。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p><p>该奖项为阿斯特里亚提供资金，用于在脊髓损伤受试者中重新启动AST-OPC1的临床开发，并扩大针对未来关键试验的目标人群中剂量递增的临床试验。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p><p>AST-OPC1是人类胚胎干细胞（hESCs）衍生而来且含有少突胶质母细胞（OPCs）的细胞群。OPCs及其成熟衍生物-少突胶质细胞为脊髓和大脑中的神经细胞提供重要的功能支持。阿斯特里亚最近公布了在神经完全性胸脊髓损伤患者中低剂量AST-OPC1的第一阶段临床试验结果。结果表明，AST-OPC1被成功地递送到损伤的脊髓部位。在AST-OPC1给药后的2-3年内，患者在详细的随访评估(包括频繁的神经系统检查和核磁共振成像)中没有显示与细胞相关的严重不良事件的证据。移植后一年对受试者的免疫监测显示没有对AST-OPC1产生抗体或细胞免疫反应。五名受试者中的四名受试者，在2-3年随访期内进行的连续核磁共振成像扫描表明，脊髓空洞可能已经减少，AST-OPC1可能在减少脊髓组织恶化方面具有一定积极作用。根据脊髓损伤神经分类国际标准(ISNCSCI)检查的评估，试验中的五名受试者没有出现意外的神经退化或改善。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p><p>来自CIRM的战略伙伴关系三期捐款将为阿斯特里亚斯提供资金，以支持AST-OPC1在脊髓损伤受试者中的下一次临床试验，并为阿斯特里亚斯的产品开发努力提供资金，以改进和扩大生产方法，支持后期试验并最终商业化。CIRM的资助将取决于美国食品和药物管理局对试验的批准、阿斯特里亚斯和CIRM之间最终协议的完成，以及阿斯特里亚斯在实现某些预定项目里程碑方面的持续进展。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12988?w=300&h=300&titlename=%E8%83%9A%E7%8A%B6%E4%BD%93%E5%BD%A2%E6%88%90%E5%90%8E24%E5%B0%8F%E6%97%B6","url":"https://web.archive.org/web/20221028211915/https://img01.sogoucdn.com/app/a/200698/sogou_science_12988","rw":300,"rh":300,"title":"胚状体形成后24小时","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14995394979168782","title":"关注和争议","versionId":"54114251517780240","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3><b>负面效应</b></h3></p><p>将胚胎干细胞移植到患者体内作为治疗的主要关注点是它们具有形成肿瘤(包括畸胎瘤)的能力。<sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup> 安全问题促使美国食品和药物管理局暂停第一次胚胎干细胞临床试验，但是并没有观察到肿瘤的发生。</p><p>提高胚胎干细胞临床应用安全性的主要策略是将胚胎干细胞分化为特定的细胞类型(如神经元、肌肉、肝细胞)，这些细胞类型降低或消除了引起肿瘤的能力。分化后，通过流式细胞术对细胞进行分选以进一步纯化。胚胎干细胞从本质上推测比用基因整合病毒载体产生的诱导多能干细胞更安全，因为它们没有用与癌症相关的基因如c-Myc基因进行基因修饰。然而，诱导多能干细胞所需的基因在胚胎干细胞中表达量非常高，这些基因（包括Myc）对胚胎干细胞的自我更新和多能性至关重要，<sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup> 并且通过消除c-Myc的表达量来提高安全性的潜在策略不太可能保持细胞的“干细胞性”。然而，N-myc和L-myc已经被发现可以在同等效率下替代c-myc来诱导多能干细胞。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup>最近诱导多能性的方案通过使用非整合的核糖核酸病毒载体，如仙台病毒或信使核糖核酸（mRNA)转染，完全克服了这些问题。</p><p><h3>伦理争论</h3></p><p>由于胚胎干细胞研究的性质，在这个问题上存在许多有争议的观点。由于获得胚胎干细胞需要摧毁从中获得这些细胞的胚胎，胚胎的伦理道德地位受到质疑。有些人认为，5天大的细胞团太年轻而不能称之为人，或者从体外受精诊所(实验室通常从那里获取胚胎)捐赠的胚胎，如果不加以利用最终都会变成医疗废弃物。胚胎干细胞研究的反对者则反驳说，任何胚胎都有可能成为人，因此摧毁它就是谋杀，胚胎必须受到与发育完全的人类与之相等的伦理观的保护。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14995394979168783","title":"历史","versionId":"54114251517780241","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>\n </p><ul>\n  <li>1964年:刘易斯·克莱因史密斯和小巴里·皮尔斯从畸胎瘤中分离出单一类型的细胞，畸胎瘤是一种现在已知的来源于生殖细胞的肿瘤。<sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> 这些从畸胎瘤中分离出来的细胞作为干细胞在细胞培养中复制和生长，现在被称为胚胎癌细胞（EC）。<sup><a href=\"#quote_46\" class=\"kx_ref\">[46]</a></sup> 虽然形态学和分化潜能(多能性)的相似性导致了使用胚胎癌细胞作为小鼠早期发育的体外模型，但<sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup> 胚胎癌干细胞含有遗传突变和通常在畸胎瘤发展过程中积累的异常核型。这些遗传变异进一步增强了直接从内细胞团培养多能干细胞的需求。</li>\n </ul><p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"210\" img_width=\"140\" titlename=\"马丁·埃文斯开发了一种在子宫中培养小鼠胚胎的新技术，可以从这些胚胎中获得胚胎干细胞的衍生物。\" data-src=\"https://img04.sogoucdn.com/app/a/200698/sogou_science_12989\"> </p><p>\n </p><ul>\n  <li>1981年:胚胎干细胞首先由两个独立的研究小组从小鼠胚胎中获得。剑桥大学遗传学系的马丁·埃文斯和马修·考夫曼于7月首次发表论文表明，他们开发了一种在子宫中培养小鼠胚胎的新技术，这种新技术可以增加细胞数量，从而从这些胚胎中获得胚胎干细胞的衍生物。 加州大学旧金山分校解剖学系的盖尔·马丁在12月发表了她的论文，并创造了“胚胎干细胞”一词。 她表明胚胎可以在体外培养，同时胚胎干细胞可以从这些胚胎中获得。</li>\n  <li>1989年:马里奥·卡佩奇、马丁·伊文斯和奥利弗·史密西斯发表了他们的研究，详细阐述了他们对胚胎干细胞的分离和基因改造，创造了第一只“敲除小鼠”。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup> 在创造“敲除小鼠”的过程中，这篇文章为科学家提供了一种全新的研究疾病的方法。</li>\n  <li>1998年:威斯康星大学麦迪逊分校的一个团队(詹姆斯·汤姆森、约瑟夫·伊茨科维奇-埃尔多、桑德·夏皮罗、米歇尔·瓦肯茨、詹妮弗·j·斯威吉尔、维维安·马歇尔和杰弗里·琼斯)发表了一篇题为《源自人类囊胚的胚胎干细胞系》的论文。这项研究背后的研究人员不仅创造了第一批胚胎干细胞，而且认识到它们的多能性以及自我更新的能力。这篇论文的摘要指出了这一发现在发育生物学和药物发掘领域的重要意义。<sup><a href=\"#quote_49\" class=\"kx_ref\">[49]</a></sup></li>\n  <li>2001年:乔治·布什总统允许联邦资金支持大约60个——当时已经存在的——胚胎干细胞系的研究。鉴于布什允许研究的有限干细胞系已经建立，这项法律支持的胚胎干细胞研究不会引起任何伦理问题，而在联邦预算建立新的干细胞系则可能会引发伦理问题。<sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup></li>\n  <li>2006年:日本科学家山中伸弥和高桥知利发表了一篇描述从成年小鼠成纤维细胞培养物中诱导多能干细胞的论文。诱导多能干细胞（iPSCs）是一个巨大的发现，因为它们似乎与胚胎干细胞一致，而且可以在不引发同样道德争议的情况下使用。<sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup></li>\n  <li>2009年1月:美国食品和药物管理局(FDA)批准Geron公司对其人类胚胎干细胞衍生的对脊髓损伤治疗的第一阶段试验。这项声明得到科学界的热烈欢迎，但也受到干细胞反对者的警惕。然而，治疗细胞来源于乔治·布什的胚胎干细胞政策下批准的细胞系。<sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup></li>\n  <li>2009年3月:巴拉克·奥巴马总统签署了第13505号行政命令，取消了前总统政府对联邦资助人类干细胞的限制。这将使国家卫生研究院（NIH）能够为人类胚胎干细胞研究提供资助。该文件还指出，国家卫生研究院必须在命令签署后的120天内提供修订后的联邦资助指南。<sup><a href=\"#quote_53\" class=\"kx_ref\">[53]</a></sup></li>\n </ul><p></p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12989?w=140&h=210&titlename=%E9%A9%AC%E4%B8%81%C2%B7%E5%9F%83%E6%96%87%E6%96%AF%E5%BC%80%E5%8F%91%E4%BA%86%E4%B8%80%E7%A7%8D%E5%9C%A8%E5%AD%90%E5%AE%AB%E4%B8%AD%E5%9F%B9%E5%85%BB%E5%B0%8F%E9%BC%A0%E8%83%9A%E8%83%8E%E7%9A%84%E6%96%B0%E6%8A%80%E6%9C%AF%EF%BC%8C%E5%8F%AF%E4%BB%A5%E4%BB%8E%E8%BF%99%E4%BA%9B%E8%83%9A%E8%83%8E%E4%B8%AD%E8%8E%B7%E5%BE%97%E8%83%9A%E8%83%8E%E5%B9%B2%E7%BB%86%E8%83%9E%E7%9A%84%E8%A1%8D%E7%94%9F%E7%89%A9%E3%80%82","url":"https://web.archive.org/web/20221028211915/https://img04.sogoucdn.com/app/a/200698/sogou_science_12989","rw":140,"rh":210,"title":"马丁·埃文斯开发了一种在子宫中培养小鼠胚胎的新技术，可以从这些胚胎中获得胚胎干细胞的衍生物。","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14995394995945987","title":"胚胎干细胞的来源和培养的技术和条件","versionId":"54114251517780242","lemmaId":10536,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82812762,"name":"雷克斯班纳","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599550607,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>源自人类</h3></p><p>体外受精会产生多个胚胎。这会产生一些过剩的胚胎不用于临床或不适合植入患者体内，因此可以在征得供体同意的情况下可能获得捐赠。人类胚胎干细胞可以从这些捐赠的胚胎中获得，或者还可以使用患者的细胞和捐赠的卵子从克隆的胚胎中提取。<sup><a href=\"#quote_54\" class=\"kx_ref\">[54]</a></sup> 胚胎囊胚期的内细胞团(感兴趣的细胞)与滋养层细胞分离，滋养层细胞将来分化为胚外组织。从免疫外科来说，通过抗体结合到滋养层细胞并且被另一种溶液去除，与此同时进行机械解剖以实现（内细胞团的）分离。获得的内部细胞团细胞被接种到提供支持的细胞上。内部细胞团细胞附着在一起并进一步扩张形成未分化的人胚胎细胞系。每天需给这些细胞提供养分，而且每四至七天需通过酶解或机械分离一次。为了发生分化，将人胚胎干细胞系从支持细胞中取出以形成胚状体，然后与含有必要信号分子的血清共培养，或者移植到三维支架中以产生。<sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup> </p><p><h3><b>源</b>自其他动物</h3></p><p>胚胎干细胞来源于早期胚胎的内细胞团，这些细胞团是从供体雌性动物身上获得的。马丁·埃文斯和马修·考夫曼报道了一种延迟胚胎植入的技术，该技术允许内细胞团数量增加。这个过程包括摘除捐献者母亲的卵巢，给她注射黄体酮以改变激素环境，从而使胚胎在子宫中保持自由。在子宫内培养4-6天后，胚胎即被收获并在体外培养至内细胞团形成“卵圆筒状结构”，此时内细胞团分离成单细胞，并铺在用丝裂霉素c处理的成纤维细胞上(以防止成纤维细胞进行有丝分裂)。克隆的细胞系是由单个细胞生长而成的。埃文斯和考夫曼表明，从这些培养物中生长出来的细胞可以形成畸胎瘤和胚状体，以及可以在体外分化，以上结果表明这些细胞具有多能性。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup> </p><p>盖尔·马丁以不同的方式获得和培养她的胚胎干细胞。她从交配后大约76小时的捐献者母亲身上取出胚胎，并在含血清的培养基中培养过夜。第二天，她通过显微外科手术从晚期胚泡剥离出内细胞团。提取的内细胞团在含有血清的培养基并用丝裂霉素c处理的成纤维细胞上培养，并根据胚胎干细胞的状态作调节。大约一周后，细胞系形成。这些细胞在培养物中生长并表现出多能特性，如形成畸胎瘤、进行体外分化和形成胚状体的能力。马丁称这些细胞为胚胎干细胞。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup> </p><p>目前已知饲养细胞提供的白血病抑制因子（LIF）和血清中提供的骨形态发生蛋白（BMPs）对于阻止胚胎干细胞的分化是必需的。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup><sup><a href=\"#quote_57\" class=\"kx_ref\">[57]</a></sup> 这些因子对胚胎干细胞的衍生效率极其重要。此外，研究表明不同的小鼠品系具有不同的分离胚胎干细胞的效率。<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup> 小鼠胚胎干细胞目前的用途包括制备转基因小鼠，包括“基因敲除小鼠”。对于人类治疗，需要具有患者特异性多能细胞。人类胚胎干细胞的生成产生更加困难，并面临伦理问题。因此，除了人类胚胎干细胞研究之外，许多团队更关注于诱导多能干细胞(iPS cells)的产生。<sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup> </p><p><h3>新<b>细胞系来源的潜在方法</b></h3></p><p>2006年8月23日，科学类杂志《自然》在线发表了罗伯特·兰扎博士(马萨诸塞州伍斯特市高级细胞技术医学主任)的一篇短文，声称他的团队找到了一种在不破坏真正胚胎的情况下提取胚胎干细胞的方法。<sup><a href=\"#quote_60\" class=\"kx_ref\">[60]</a></sup> 这一技术成就将有可能使科学家们能够利用美国公共资金研究新的胚胎干细胞系，因为当时美国联邦资金仅限于利用2001年8月以前获得的胚胎干细胞系进行研究。直到2009年3月，限制被解除。<sup><a href=\"#quote_61\" class=\"kx_ref\">[61]</a></sup> </p><p><h3>诱导多能干细胞</h3></p><p>iPSC技术是由日本京都的山中伸弥实验室首创的，该实验室在2006年表明向成体细胞中导入四种编码特定转录因子的基因可以将成体细胞转化为多能干细胞。<sup><a href=\"#quote_62\" class=\"kx_ref\">[62]</a></sup> 他与约翰·古登爵士一起获得了2012年诺贝尔奖，“因为他们发现成熟细胞可以被重编程而具有多能性。” <sup><a href=\"#quote_63\" class=\"kx_ref\">[63]</a></sup> </p><p>2007年，研究表明，通过将三种基因(<i>Oct4</i>、<i>Sox2</i>和<i>Klf4</i>)导入已分化的细胞，可以产生与胚胎干细胞高度相似的多能干细胞。<sup><a href=\"#quote_64\" class=\"kx_ref\">[64]</a></sup> 这些基因的导入可以将已分化的细胞“重编程”为多能干细胞，从而可以在没有胚胎的情况下产生多能干细胞。因为关于胚胎干细胞的伦理问题通常是关于它们从终止的胚胎中衍生出来的，所以人们相信对这些重编程的“诱导多能干细胞”(iPS细胞)可能存在更少的争议。人类和小鼠细胞都可以通过这种方法重新编程，在无需胚胎的情况下产生人类多能干细胞和小鼠多能干细胞。<sup><a href=\"#quote_65\" class=\"kx_ref\">[65]</a></sup> </p><p>这可以产生可能用于细胞替代治疗的患者特异性胚胎干细胞系。此外，这将允许从患有各种遗传疾病的患者中产生胚胎干细胞系，并将为研究这些疾病提供宝贵的模型。</p><p>然而，正如《科学》杂志2007年12月6日在线报道的那样，作为诱导多能干细胞(iPS)细胞技术能够接连不断地引起新疗法的第一个标志，马萨诸塞州剑桥怀特黑德生物医学研究所的鲁道夫·杰尼斯奇(Rudolf Jaenisch)领导的一个研究小组使用该技术来治疗小鼠镰状细胞性贫血。<sup><a href=\"#quote_66\" class=\"kx_ref\">[66]</a></sup><sup><a href=\"#quote_67\" class=\"kx_ref\">[67]</a></sup> </p><p>2008年1月16日，一家总部设在加州的斯坦玛根公司宣布，他们已经从取自成年人的单一皮肤细胞中创造了第一个成熟的人类克隆胚胎。这些胚胎可以为与胚胎干细胞匹配成功的患者采集。<sup><a href=\"#quote_68\" class=\"kx_ref\">[68]</a></sup> </p><p><h3><b>细胞培养中的试剂污染</b></h3></p><p>2005年1月24日，《自然医学》在线发表的一项研究指出，可用于联邦资助研究的人类胚胎干细胞被用于培养细胞的培养基中的非人类分子污染。<sup><a href=\"#quote_69\" class=\"kx_ref\">[69]</a></sup> 使用小鼠细胞和其他动物细胞来维持具有高度分裂活性的干细胞的多能性是一种常见的技术。据加利福尼亚大学圣地亚哥分校的科学家称，他们发现生长培养基中的非人类唾液酸会降低胚胎干细胞在人类中的潜在用途。<sup><a href=\"#quote_70\" class=\"kx_ref\">[70]</a></sup> </p><p>然而，2005年3月8日在线发表在《柳叶刀》医学杂志上的一项研究详细介绍了一种新的干细胞系，这种干细胞系是在完全无细胞和无血清的条件下从人类胚胎中获得的。在超过6个月的未分化增殖后，这些细胞在体外和畸胎瘤中显示出形成所有三个胚胎胚层衍生细胞的潜力。利用已建立的干细胞系，这些特性同样可以成功维持(超过30代)。<sup><a href=\"#quote_71\" class=\"kx_ref\">[71]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"Thomson; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM (1998). \"Blastocysts Embryonic Stem Cell Lines Derived from Human\". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"\"NIH Stem Cell Basics. What are embryonic stem cells?\".","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Baldwing A (2009). \"Morality and human embryo research. Introduction to the Talking Point on morality and human embryo research\". EMBO Reports. 10 (4): 299–300. doi:10.1038/embor.2009.37. PMC 2672902. PMID 19337297.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"Nakaya, Andrea C. (August 1, 2011). Biomedical ethics. San Diego, CA: ReferencePoint Press. p. 96. ISBN 978-1601521576.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"\"Introduction: What are stem cells, and why are they important?\". National Institutes of Health. Retrieved 28 October 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Carla A Herberts; Marcel SG Kwa; Harm PH Hermsen (2011). \"Risk factors in the development of stem cell therapy\". Journal of Translational Medicine. 9 (29): 29. doi:10.1186/1479-5876-9-29. PMC 3070641. PMID 21418664.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Thomson, J. A.; Itskovitz-Eldor, J; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. S.; Jones, J. M. (1998). \"Embryonic Stem Cell Lines Derived from Human Blastocysts\". Science. 282 (5391): 1145–7. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"Ying; Nichols, J; Chambers, I; Smith, A (2003). \"BMP Induction of Id Proteins Suppresses Differentiation and Sustains Embryonic Stem Cell Self-Renewal in Collaboration with STAT3\". Cell. 115 (3): 281–292. doi:10.1016/S0092-8674(03)00847-X. PMID 14636556.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Template:Cite PMID: 25288119","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"PMID 26889666（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"PMID 15703208（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"PMID 19968627（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"PMID 19139263（PubMed） 本引用来源将会在数十分钟后自动完成。您可以检查英文对应模板或手动扩充","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Mahla, Ranjeet (July 19, 2016). \"Stem Cell Applications in Regenerative Medicine and Disease Therapeutics\". International Journal of Cell Biology. 2016: 6940283. doi:10.1155/2016/6940283. PMC 4969512. PMID 27516776.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Levenberg, S. (2002). \"Endothelial cells derived from human embryonic stem cells\". Proceedings of the National Academy of Sciences. 99 (7): 4391–4396. Bibcode:2002PNAS...99.4391L. doi:10.1073/pnas.032074999. PMC 123658. PMID 11917100.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Davila, JC; Cezar, GG; Thiede, M; Strom, S; Miki, T; Trosko, J (2004). \"Use and application of stem cells in toxicology\". Toxicological Sciences. 79 (2): 214–23. doi:10.1093/toxsci/kfh100. PMID 15014205.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Siu, CW; Moore, JC; Li, RA (2007). \"Human embryonic stem cell-derived cardiomyocytes for heart therapies\". Cardiovascular & Hematological Disorders Drug Targets. 7 (2): 145–52. doi:10.2174/187152907780830851. PMID 17584049.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"Perrier, A. L. (2004). \"Derivation of midbrain dopamine neurons from human embryonic stem cells\". Proceedings of the National Academy of Sciences. 101 (34): 12543–12548. Bibcode:2004PNAS..10112543P. doi:10.1073/pnas.0404700101. PMC 515094. PMID 15310843.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"Parish, CL; Arenas, E (2007). \"Stem-cell-based strategies for the treatment of Parkinson's disease\". Neuro-Degenerative Diseases. 4 (4): 339–47. doi:10.1159/000101892. PMID 17627139.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"Waese, EY; Kandel, RA; Stanford, WL (2008). \"Application of stem cells in bone repair\". Skeletal Radiology. 37 (7): 601–8. doi:10.1007/s00256-007-0438-8. PMID 18193216.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"d'Amour, KA; Bang, AG; Eliazer, S; Kelly, OG; Agulnick, AD; Smart, NG; Moorman, MA; Kroon, E; Carpenter, MK; Baetge, EE (2006). \"Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells\". Nature Biotechnology. 24 (11): 1392–401. doi:10.1038/nbt1259. PMID 17053790.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"Colen, B.D. (9 October 2014) Giant leap against diabetes The Harvard Gazette, Retrieved 24 November 2014","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"Menasché, Phillip; Vanneaux, Valérie; Fabreguettes, Jean-Roch; Bel, Alain; Tosca, Lucie; Garcia, Sylvie (21 March 2015). \"Towards a clinical use of human embryonic stem cell derived-cardiac progenitors: a translational experience\". European Heart Journal. 36 (12): 743–750. doi:10.1093/eurheartj/ehu192. PMID 24835485.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"Jensen, J; Hyllner, J; Björquist, P (2009). \"Human embryonic stem cell technologies and drug discovery\". Journal of Cellular Physiology. 219 (3): 513–9. doi:10.1002/jcp.21732. PMID 19277978.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Söderdahl, T; Küppers-Munther, B; Heins, N; Edsbagge, J; Björquist, P; Cotgreave, I; Jernström, B (2007). \"Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells\". Toxicology in Vitro. 21 (5): 929–37. doi:10.1016/j.tiv.2007.01.021. PMID 17346923.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"\"Dr. Yury Verlinsky, 1943–2009: Expert in reproductive technology\" Chicago Tribune, July 20, 2009","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"Mao Z, Bozzella M, Seluanov A, Gorbunova V (September 2008). \"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells\". Cell Cycle. 7 (18): 2902–6. doi:10.4161/cc.7.18.6679. PMC 2754209. PMID 18769152.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Tichy ED, Pillai R, Deng L, et al. (November 2010). \"Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double-strand DNA breaks\". Stem Cells Dev. 19 (11): 1699–711. doi:10.1089/scd.2010.0058. PMC 3128311. PMID 20446816.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"Hong Y, Stambrook PJ (October 2004). \"Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation\". Proc. Natl. Acad. Sci. U.S.A. 101 (40): 14443–8. Bibcode:2004PNAS..10114443H. doi:10.1073/pnas.0401346101. PMC 521944. PMID 15452351.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"Aladjem MI, Spike BT, Rodewald LW, et al. (January 1998). \"ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage\". Curr. Biol. 8 (3): 145–55. doi:10.1016/S0960-9822(98)70061-2. PMID 9443911.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"Bernstein C, Bernstein H, Payne CM, Garewal H (June 2002). \"DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis\". Mutat. Res. 511 (2): 145–78. doi:10.1016/S1383-5742(02)00009-1. PMID 12052432.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ (March 2002). \"Embryonic stem cells and somatic cells differ in mutation frequency and type\". Proc. Natl. Acad. Sci. U.S.A. 99 (6): 3586–90. Bibcode:2002PNAS...99.3586C. doi:10.1073/pnas.062527199. PMC 122567. PMID 11891338.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"\"FDA approves human embryonic stem cell study - CNN.com\". January 23, 2009. Retrieved May 1, 2010.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"Keirstead HS, Nistor G, Bernal G, et al. (2005). \"Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury\". J. Neurosci. 25 (19): 4694–705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"Reinberg, Steven (2009-01-23) FDA OKs 1st Embryonic Stem Cell Trial. The Washington Post","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"Geron comments on FDA hold on spinal cord injury trial. geron.com (August 27, 2009)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"Vergano, Dan (11 October 2010). \"Embryonic stem cells used on patient for first time\". USA Today. Retrieved 12 October 2010.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"Brown, Eryn (November 15, 2011). \"Geron exits stem cell research\". LA Times. Retrieved 2011-11-15.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"\"Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program\". iPScell.com. October 1, 2013.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"California Institute of Regenerative Medicine. BioTime, Inc.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"Knoepfler, Paul S. (2009). \"Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine\". Stem Cells. 27 (5): 1050–6. doi:10.1002/stem.37. PMC 2733374. PMID 19415771.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"Varlakhanova, Natalia V.; Cotterman, Rebecca F.; Devries, Wilhelmine N.; Morgan, Judy; Donahue, Leah Rae; Murray, Stephen; Knowles, Barbara B.; Knoepfler, Paul S. (2010). \"Myc maintains embryonic stem cell pluripotency and self-renewal\". Differentiation. 80 (1): 9–19. doi:10.1016/j.diff.2010.05.001. PMC 2916696. PMID 20537458.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Wernig, Marius; Meissner, Alexander; Cassady, John P; Jaenisch, Rudolf (2008). \"C-Myc is Dispensable for Direct Reprogramming of Mouse Fibroblasts\". Cell Stem Cell. 2 (1): 10–2. doi:10.1016/j.stem.2007.12.001. PMID 18371415.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":44,"type":"book","title":"King, Nancy; Perrin, Jacob (July 7, 2014). \"Ethical issues in stem cell research and therapy\". Stem Cell Research and Therapy. 5 (4): 85. doi:10.1186/scrt474. PMC 4097842.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":45,"type":"book","title":"Kleinsmith LJ, Pierce GB Jr (1964). \"Multipotentiality of Single Embryoncal Carcinoma Cells\". Cancer Res. 24: 1544–51. PMID 14234000.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":46,"type":"book","title":"Andrews P, Matin M, Bahrami A, Damjanov I, Gokhale P, Draper J (2005). \"Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin\" (PDF). Biochem Soc Trans. 33 (Pt 6): 1526–30. doi:10.1042/BST20051526. PMID 16246161.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":47,"type":"book","title":"Martin GR (1980). \"Teratocarcinomas and mammalian embryogenesis\". Science. 209 (4458): 768–76. Bibcode:1980Sci...209..768M. doi:10.1126/science.6250214. PMID 6250214.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":48,"type":"book","title":"\"The 2007 Nobel Prize in Physiology or Medicine - Advanced Information\". Nobel Prize. Nobel Media.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":49,"type":"book","title":"Thompson, James A.; Itskovitz-Eldor, Joseph; Shapiro, Sander S.; Waknitz, Michelle A.; Swiergiel, Jennifer J.; Marshall, Vivienne S.; Jones, Jeffrey M. (6 November 1998). \"Embryonic Stem Cell Lines Derived From Human Blastocyst\". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":50,"type":"book","title":"\"President George W. Bush's address on stem cell research\". CNN Inside Politics. CNN. Aug 9, 2001.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":51,"type":"book","title":"Yamanaka, Shinya; Takahashi, Kazutoshi (25 Aug 2006). \"Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors\". Cell. 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":52,"type":"book","title":"Wadman, Meredith (27 January 2009). \"Stem cells ready for primetime\". Nature. Nature. 457 (7229): 516. doi:10.1038/457516a. PMID 19177087.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":53,"type":"book","title":"\"Executive Order 13505—Removing Barriers To Responsible Scientific Research Involving Human Stem Cells\" (PDF). Federal Register: Presidential Documents. 74 (46). 11 March 2009.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":54,"type":"book","title":"Mountford, JC (2008). \"Human embryonic stem cells: origins, characteristics and potential for regenerative therapy\". Transfus Med. 18 (1): 1–12. doi:10.1111/j.1365-3148.2007.00807.x. PMID 18279188.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":55,"type":"book","title":"Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998). \"Embryonic stem cell lines derived from human blastocysts\". Science. 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":56,"type":"book","title":"Evans M, Kaufman M (1981). \"Establishment in culture of pluripotent cells from mouse embryos\". Nature. 292 (5819): 154–6. Bibcode:1981Natur.292..154E. doi:10.1038/292154a0. PMID 7242681.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":57,"type":"book","title":"Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA, Gough NM (1988). \"Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells\". Nature. 336 (6200): 684–687. Bibcode:1988Natur.336..684W. doi:10.1038/336684a0. PMID 3143916.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":58,"type":"book","title":"Ledermann B, Bürki K (1991). \"Establishment of a germ-line competent C57BL/6 embryonic stem cell line\". Exp Cell Res. 197 (2): 254–258. doi:10.1016/0014-4827(91)90430-3. PMID 1959560.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":59,"type":"book","title":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007). \"Induction of pluripotent stem cells from adult human fibroblasts by defined factors\". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. PMID 18035408.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":60,"type":"book","title":"Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R (2006). \"Human embryonic stem cell lines derived from single blastomeres\". Nature. 444 (7118): 481–5. Bibcode:2006Natur.444..481K. doi:10.1038/nature05142. PMID 16929302.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":61,"type":"book","title":"US scientists relieved as Obama lifts ban on stem cell research, The Guardian, 10 March 2009","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":62,"type":"book","title":"Takahashi, K; Yamanaka, S (2006). \"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors\". Cell. 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":63,"type":"book","title":"\"The Nobel Prize in Physiology or Medicine – 2012 Press Release\". Nobel Media AB. 8 October 2012.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":64,"type":"book","title":"Wernig, Marius; Meissner, Alexander; Foreman, Ruth; Brambrink, Tobias; Ku, Manching; Hochedlinger, Konrad; Bernstein, Bradley E.; Jaenisch, Rudolf (2007-07-19). \"In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state\". Nature. 448 (7151): 318–324. Bibcode:2007Natur.448..318W. doi:10.1038/nature05944. ISSN 1476-4687. PMID 17554336.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":65,"type":"book","title":"\"Embryonic stem cells made without embryos\". Reuters. 2007-11-21.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":66,"type":"book","title":"Weiss, Rick (2007-12-07). \"Scientists Cure Mice Of Sickle Cell Using Stem Cell Technique: New Approach Is From Skin, Not Embryos\". The Washington Post. pp. A02.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":67,"type":"book","title":"Hanna, J.; Wernig, M.; Markoulaki, S.; Sun, C.-W.; Meissner, A.; Cassady, J. P.; Beard, C.; Brambrink, T.; Wu, L.-C.; Townes, T. M.; Jaenisch, R. (2007). \"Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin\". Science. 318 (5858): 1920–3. Bibcode:2007Sci...318.1920H. doi:10.1126/science.1152092. PMID 18063756.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":68,"type":"book","title":"Helen Briggs (2008-01-17). \"US team makes embryo clone of men\". BBC. pp. A01.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":69,"type":"book","title":"Ebert, Jessica (24 January 2005). \"Human stem cells trigger immune attack\". Nature News. London: Nature Publishing Group. doi:10.1038/news050124-1. Archived from the original on 2010-09-24. Retrieved 2009-02-27.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":70,"type":"book","title":"Martin MJ, Muotri A, Gage F, Varki A (2005). \"Human embryonic stem cells express an immunogenic nonhuman sialic acid\". Nat. Med. 11 (2): 228–32. doi:10.1038/nm1181. PMID 15685172.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":71,"type":"book","title":"Klimanskaya I, Chung Y, Meisner L, Johnson J, West MD, Lanza R (2005). \"Human embryonic stem cells derived without feeder cells\". Lancet. 365 (9471): 1636–41. doi:10.1016/S0140-6736(05)66473-2. PMID 15885296.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":6714,"auditType":0,"synonyms":["ES细胞","胚性干细胞"],"showEditTime":"2019.12.13 18:45","auditors":[{"uid":0,"name":"Ki.κe","pic":"https://web.archive.org/web/20221028211915/https://wx.qlogo.cn/mmopen/vi_32/y67kfr32Doib4wg71Jiau7jVWvharic3nRKgdRRQSl6koeQJCo0GQs2Krw0vwdFRsOWnHIQOwAZsSg5lIkIrFCOcQ/132","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false}],"hasZhishiNav":false,"auditInfos":{},"isHistory":false};</script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./536.胚胎干细胞 - 搜狗科学百科_files/main_edf0f08.js.download"></script>
</body></html>